For Canopy Growth (CGC -1.82%), as with most cannabis stocks, the next key catalyst has nothing to do with the industry or the economy. Instead, what will likely cause marijuana stocks to surge or sink from here has to do with an upcoming decision from the U.S. Drug Enforcement Administration (DEA).
This decision wouldn't resolve all of Canopy's regulatory headwinds, but since it could spark another round of bullishness, let's dive into the latest.
Image source: Getty Images.
The DEA, Schedule III, and what it could mean for Canopy Growth The DEA's efforts to reschedule marijuana to Schedule III have been months in the making, with hearings on the matter only taking place recently. Legal experts seem confident that these hearings will lead to a decision that bodes well for the cannabis industry, but it's unclear whether a final decision will finally arrive.
Still, given President Donald Trump's executive order issued last December, which called for reclassification to occur "in the most expeditious manner possible," a final decision could arrive far sooner. While it's not a solution for all regulatory hurdles, it would signal that Canopy is moving closer toward consolidating its U.S. affiliate, Canopy USA, into the parent company. Canopy USA itself would benefit by being no longer subject to the deduction limitations imposed by section 280E of the Internal Revenue Code.
Today's Change
(
-1.82
%) $
-0.02
Current Price
$
0.89
Buy now, or watch and wait? So, is it time to buy Canopy ahead of the Rescheduling decision, or to watch and wait? Based on past price performance, I would go with the latter. Remember that in April, following the last bit of DEA-related legalization news, Canopy and peers surged briefly, then sank back down.
The same thing could repeat itself if the U.S. Federal Government moves ahead with a broad rescheduling of cannabis. Investors could bid shares up on the headlines at first, then retreat upon reading the details. As the best approach entails holding cannabis stocks as a long-term wager on legalization, not a short-term binary bet, waiting for the next round of regulatory progress to take shape remains your best move.
Canopy Growth Corporation (CGC - Free Report) closed at $0.89 in the latest trading session, marking a -1.82% move from the prior day. The stock trailed the S&P 500, which registered a daily gain of 0.05%. Meanwhile, the Dow gained 0.46%, and the Nasdaq, a tech-heavy index, lost 0.64%.
Prior to today's trading, shares of the company had lost 0.88% lagged the Medical sector's gain of 3.64% and the S&P 500's gain of 0.61%.
The investment community will be paying close attention to the earnings performance of Canopy Growth Corporation in its upcoming release. On that day, Canopy Growth Corporation is projected to report earnings of -$0.04 per share, which would represent year-over-year growth of 71.43%. At the same time, our most recent consensus estimate is projecting a revenue of $58.52 million, reflecting a 12.25% rise from the equivalent quarter last year.
For the entire fiscal year, the Zacks Consensus Estimates are projecting earnings of -$0.11 per share and a revenue of $243.57 million, representing changes of +75.56% and +18.26%, respectively, from the prior year.
It is also important to note the recent changes to analyst estimates for Canopy Growth Corporation. These revisions help to show the ever-changing nature of near-term business trends. With this in mind, we can consider positive estimate revisions a sign of optimism about the business outlook.
Our research suggests that these changes in estimates have a direct relationship with upcoming stock price performance. To take advantage of this, we've established the Zacks Rank, an exclusive model that considers these estimated changes and delivers an operational rating system.
The Zacks Rank system, ranging from #1 (Strong Buy) to #5 (Strong Sell), possesses a remarkable history of outdoing, externally audited, with #1 stocks returning an average annual gain of +25% since 1988. The Zacks Consensus EPS estimate remained stagnant within the past month. Canopy Growth Corporation currently has a Zacks Rank of #3 (Hold).
The Medical - Products industry is part of the Medical sector. With its current Zacks Industry Rank of 166, this industry ranks in the bottom 33% of all industries, numbering over 250.
The Zacks Industry Rank evaluates the power of our distinct industry groups by determining the average Zacks Rank of the individual stocks forming the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Remember to apply Zacks.com to follow these and more stock-moving metrics during the upcoming trading sessions.
Canopy Growth Corporation (CGC - Free Report) closed at $0.91 in the latest trading session, marking a -2.67% move from the prior day. The stock fell short of the S&P 500, which registered a loss of 0.14% for the day. Meanwhile, the Dow lost 0.01%, and the Nasdaq, a tech-heavy index, lost 0.57%.
The stock of company has fallen by 1.16% in the past month, lagging the Medical sector's gain of 5.8% and the S&P 500's gain of 0.25%.
Investors will be eagerly watching for the performance of Canopy Growth Corporation in its upcoming earnings disclosure. The company is expected to report EPS of -$0.04, up 71.43% from the prior-year quarter. Meanwhile, the latest consensus estimate predicts the revenue to be $58.52 million, indicating a 12.25% increase compared to the same quarter of the previous year.
For the full year, the Zacks Consensus Estimates project earnings of -$0.11 per share and a revenue of $243.57 million, demonstrating changes of +75.56% and +18.26%, respectively, from the preceding year.
Investors might also notice recent changes to analyst estimates for Canopy Growth Corporation. Recent revisions tend to reflect the latest near-term business trends. As a result, we can interpret positive estimate revisions as a good sign for the business outlook.
Based on our research, we believe these estimate revisions are directly related to near-term stock moves. To utilize this, we have created the Zacks Rank, a proprietary model that integrates these estimate changes and provides a functional rating system.
The Zacks Rank system, which ranges from #1 (Strong Buy) to #5 (Strong Sell), has an impressive outside-audited track record of outperformance, with #1 stocks generating an average annual return of +25% since 1988. The Zacks Consensus EPS estimate remained stagnant within the past month. Canopy Growth Corporation is currently sporting a Zacks Rank of #3 (Hold).
The Medical - Products industry is part of the Medical sector. At present, this industry carries a Zacks Industry Rank of 168, placing it within the bottom 32% of over 250 industries.
The Zacks Industry Rank is ordered from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Keep in mind to rely on Zacks.com to watch all these stock-impacting metrics, and more, in the succeeding trading sessions.
Canopy Growth Corporation (CGC - Free Report) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look at some of the facts that could shape the stock's performance in the near term.
Over the past month, shares of this company have returned -1.2%, compared to the Zacks S&P 500 composite's +0.3% change. During this period, the Zacks Medical - Products industry, which Canopy Growth falls in, has gained 3.4%. The key question now is: What could be the stock's future direction?
Although media reports or rumors about a significant change in a company's business prospects usually cause its stock to trend and lead to an immediate price change, there are always certain fundamental factors that ultimately drive the buy-and-hold decision.
Earnings Estimate RevisionsHere at Zacks, we prioritize appraising the change in the projection of a company's future earnings over anything else. That's because we believe the present value of its future stream of earnings is what determines the fair value for its stock.
Our analysis is essentially based on how sell-side analysts covering the stock are revising their earnings estimates to take the latest business trends into account. When earnings estimates for a company go up, the fair value for its stock goes up as well. And when a stock's fair value is higher than its current market price, investors tend to buy the stock, resulting in its price moving upward. Because of this, empirical studies indicate a strong correlation between trends in earnings estimate revisions and short-term stock price movements.
For the current quarter, Canopy Growth is expected to post a loss of $0.04 per share, indicating a change of +71.4% from the year-ago quarter. The Zacks Consensus Estimate remained unchanged over the last 30 days.
The consensus earnings estimate of -$0.11 for the current fiscal year indicates a year-over-year change of +75.6%. This estimate has remained unchanged over the last 30 days.
For the next fiscal year, the consensus earnings estimate of $0.09 indicates a change of +18.2% from what Canopy Growth is expected to report a year ago. Over the past month, the estimate has remained unchanged.
With an impressive externally audited track record, our proprietary stock rating tool -- the Zacks Rank -- is a more conclusive indicator of a stock's near-term price performance, as it effectively harnesses the power of earnings estimate revisions. The size of the recent change in the consensus estimate, along with three other factors related to earnings estimates, has resulted in a Zacks Rank #3 (Hold) for Canopy Growth.
The chart below shows the evolution of the company's forward 12-month consensus EPS estimate:
12 Month EPS
Revenue Growth ForecastWhile earnings growth is arguably the most superior indicator of a company's financial health, nothing happens as such if a business isn't able to grow its revenues. After all, it's nearly impossible for a company to increase its earnings for an extended period without increasing its revenues. So, it's important to know a company's potential revenue growth.
In the case of Canopy Growth, the consensus sales estimate of $58.52 million for the current quarter points to a year-over-year change of +12.3%. The $243.57 million and $266.23 million estimates for the current and next fiscal years indicate changes of +18.3% and +9.3%, respectively.
Last Reported Results and Surprise HistoryCanopy Growth reported revenues of $51.94 million in the last reported quarter, representing a year-over-year change of +14.7%. EPS of -$0.17 for the same period compares with -$0.94 a year ago.
Compared to the Zacks Consensus Estimate of $53.26 million, the reported revenues represent a surprise of -2.47%. The EPS surprise was -183.33%.
Over the last four quarters, Canopy Growth surpassed consensus EPS estimates two times. The company topped consensus revenue estimates two times over this period.
ValuationNo investment decision can be efficient without considering a stock's valuation. Whether a stock's current price rightly reflects the intrinsic value of the underlying business and the company's growth prospects is an essential determinant of its future price performance.
Comparing the current value of a company's valuation multiples, such as its price-to-earnings (P/E), price-to-sales (P/S), and price-to-cash flow (P/CF), to its own historical values helps ascertain whether its stock is fairly valued, overvalued, or undervalued, whereas comparing the company relative to its peers on these parameters gives a good sense of how reasonable its stock price is.
As part of the Zacks Style Scores system, the Zacks Value Style Score (which evaluates both traditional and unconventional valuation metrics) organizes stocks into five groups ranging from A to F (A is better than B; B is better than C; and so on), making it helpful in identifying whether a stock is overvalued, rightly valued, or temporarily undervalued.
Canopy Growth is graded F on this front, indicating that it is trading at a premium to its peers. Click here to see the values of some of the valuation metrics that have driven this grade.
Bottom LineThe facts discussed here and much other information on Zacks.com might help determine whether or not it's worthwhile paying attention to the market buzz about Canopy Growth. However, its Zacks Rank #3 does suggest that it may perform in line with the broader market in the near term.
SMITHS FALLS, Ontario--(BUSINESS WIRE)--Canopy Growth Corporation (“Canopy Growth” or the “Company”) (TSX: WEED) (Nasdaq: CGC) announced it will be participating at the Canaccord Genuity Growth Conference in August 2026. Canopy Growth CEO Luc Mongeau will be presenting on Tuesday, August 11 at 12:00 p.m. The presentation will be publicly accessible via live webcast at https://event.summitcast.com/view/WuFmFdTcA9mVsUGHZJFU62/8jLaQ2EHsfTiWktFQKVomw, and archived for 180 days. Canaccord Genuity's.
Canopy Growth Corporation (CGC - Free Report) ended the recent trading session at $0.96, demonstrating a -1.15% change from the preceding day's closing price. This move lagged the S&P 500's daily loss of 0.79%. Meanwhile, the Dow experienced a drop of 0.26%, and the technology-dominated Nasdaq saw a decrease of 1.55%.
Shares of the company have depreciated by 2.88% over the course of the past month, underperforming the Medical sector's gain of 5.5%, and the S&P 500's gain of 4.28%.
Analysts and investors alike will be keeping a close eye on the performance of Canopy Growth Corporation in its upcoming earnings disclosure. On that day, Canopy Growth Corporation is projected to report earnings of -$0.04 per share, which would represent year-over-year growth of 71.43%. Simultaneously, our latest consensus estimate expects the revenue to be $58.52 million, showing a 12.25% escalation compared to the year-ago quarter.
Looking at the full year, the Zacks Consensus Estimates suggest analysts are expecting earnings of -$0.11 per share and revenue of $243.57 million. These totals would mark changes of +75.56% and +18.26%, respectively, from last year.
Investors should also note any recent changes to analyst estimates for Canopy Growth Corporation. These revisions help to show the ever-changing nature of near-term business trends. As a result, we can interpret positive estimate revisions as a good sign for the business outlook.
Our research reveals that these estimate alterations are directly linked with the stock price performance in the near future. To exploit this, we've formed the Zacks Rank, a quantitative model that includes these estimate changes and presents a viable rating system.
The Zacks Rank system, spanning from #1 (Strong Buy) to #5 (Strong Sell), boasts an impressive track record of outperformance, audited externally, with #1 ranked stocks yielding an average annual return of +25% since 1988. Over the past month, the Zacks Consensus EPS estimate has moved 13.79% lower. Canopy Growth Corporation presently features a Zacks Rank of #3 (Hold).
The Medical - Products industry is part of the Medical sector. This industry currently has a Zacks Industry Rank of 186, which puts it in the bottom 25% of all 250+ industries.
The strength of our individual industry groups is measured by the Zacks Industry Rank, which is calculated based on the average Zacks Rank of the individual stocks within these groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Be sure to follow all of these stock-moving metrics, and many more, on Zacks.com.
Canopy Growth Corporation (CGC - Free Report) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look at some of the facts that could shape the stock's performance in the near term.
Shares of this company have returned -4.5% over the past month versus the Zacks S&P 500 composite's +1.1% change. The Zacks Medical - Products industry, to which Canopy Growth belongs, has gained 2.5% over this period. Now the key question is: Where could the stock be headed in the near term?
While media releases or rumors about a substantial change in a company's business prospects usually make its stock 'trending' and lead to an immediate price change, there are always some fundamental facts that eventually dominate the buy-and-hold decision-making.
Revisions to Earnings EstimatesRather than focusing on anything else, we at Zacks prioritize evaluating the change in a company's earnings projection. This is because we believe the fair value for its stock is determined by the present value of its future stream of earnings.
We essentially look at how sell-side analysts covering the stock are revising their earnings estimates to reflect the impact of the latest business trends. And if earnings estimates go up for a company, the fair value for its stock goes up. A higher fair value than the current market price drives investors' interest in buying the stock, leading to its price moving higher. This is why empirical research shows a strong correlation between trends in earnings estimate revisions and near-term stock price movements.
Canopy Growth is expected to post a loss of $0.04 per share for the current quarter, representing a year-over-year change of +71.4%. Over the last 30 days, the Zacks Consensus Estimate has changed -50%.
The consensus earnings estimate of -$0.11 for the current fiscal year indicates a year-over-year change of +75.6%. This estimate has changed -13.8% over the last 30 days.
For the next fiscal year, the consensus earnings estimate of $0.09 indicates a change of +18.2% from what Canopy Growth is expected to report a year ago. Over the past month, the estimate has changed +80%.
Having a strong externally audited track record, our proprietary stock rating tool, the Zacks Rank, offers a more conclusive picture of a stock's price direction in the near term, since it effectively harnesses the power of earnings estimate revisions. Due to the size of the recent change in the consensus estimate, along with three other factors related to earnings estimates, Canopy Growth is rated Zacks Rank #3 (Hold).
The chart below shows the evolution of the company's forward 12-month consensus EPS estimate:
12 Month EPS
Projected Revenue GrowthEven though a company's earnings growth is arguably the best indicator of its financial health, nothing much happens if it cannot raise its revenues. It's almost impossible for a company to grow its earnings without growing its revenue for long periods. Therefore, knowing a company's potential revenue growth is crucial.
In the case of Canopy Growth, the consensus sales estimate of $58.52 million for the current quarter points to a year-over-year change of +12.3%. The $243.57 million and $266.23 million estimates for the current and next fiscal years indicate changes of +18.3% and +9.3%, respectively.
Last Reported Results and Surprise HistoryCanopy Growth reported revenues of $51.94 million in the last reported quarter, representing a year-over-year change of +14.7%. EPS of -$0.17 for the same period compares with -$0.94 a year ago.
Compared to the Zacks Consensus Estimate of $53.26 million, the reported revenues represent a surprise of -2.47%. The EPS surprise was -183.33%.
Over the last four quarters, Canopy Growth surpassed consensus EPS estimates two times. The company topped consensus revenue estimates two times over this period.
ValuationNo investment decision can be efficient without considering a stock's valuation. Whether a stock's current price rightly reflects the intrinsic value of the underlying business and the company's growth prospects is an essential determinant of its future price performance.
Comparing the current value of a company's valuation multiples, such as its price-to-earnings (P/E), price-to-sales (P/S), and price-to-cash flow (P/CF), to its own historical values helps ascertain whether its stock is fairly valued, overvalued, or undervalued, whereas comparing the company relative to its peers on these parameters gives a good sense of how reasonable its stock price is.
The Zacks Value Style Score (part of the Zacks Style Scores system), which pays close attention to both traditional and unconventional valuation metrics to grade stocks from A to F (an A is better than a B; a B is better than a C; and so on), is pretty helpful in identifying whether a stock is overvalued, rightly valued, or temporarily undervalued.
Canopy Growth is graded F on this front, indicating that it is trading at a premium to its peers. Click here to see the values of some of the valuation metrics that have driven this grade.
Bottom LineThe facts discussed here and much other information on Zacks.com might help determine whether or not it's worthwhile paying attention to the market buzz about Canopy Growth. However, its Zacks Rank #3 does suggest that it may perform in line with the broader market in the near term.
Few stocks have destroyed as much shareholder value as Canopy Growth (CGC +0.81%). Since its 2018 peak, shares of the cannabis producer have lost more than 99% of its value as the industry struggled with oversupply, regulatory delays, and years of unprofitable growth. That kind of collapse naturally raises a question: Is this finally a buying opportunity?
Moving in the right direction To be fair, Canopy Growth is a much healthier company now than it was a few years ago. Fiscal 2026 revenue increased 6% to $200.4 million, while cannabis revenue climbed 15%. Canadian medical cannabis revenue reached a record level, international cannabis sales rebounded sharply in the fourth quarter, and management continues targeting positive adjusted earnings before interest, taxes, depreciation, and amortization (EBITDA) during fiscal 2027. The balance sheet has also improved.
Image source: Getty Images.
Canopy ended fiscal 2026 with approximately $256.5 million in cash and a net cash position of $92 million, a dramatic improvement from the prior year. The company has also spent the past year reducing costs, integrating its MTL Cannabis acquisition, and narrowing operating losses. Still, despite those improvements, Canopy remains unprofitable.
Better company, better stock? Revenue growth has been relatively unimpressive, free cash flow remains negative, and the investment thesis still depends heavily on broader cannabis reform and continued execution in Canada and international medical markets. None of those outcomes is guaranteed.
There's also the issue of dilution. Over the years, Canopy has repeatedly issued new shares to strengthen its balance sheet and fund operations. Existing shareholders have paid a steep price for that financing, and future capital raises can't be ruled out if profitability takes longer than expected.
Today's Change
(
0.81
%) $
0.01
Current Price
$
0.96
To be sure, Canopy is certainly a stronger business than the one investors abandoned several years ago. Management deserves credit for improving the balance sheet and stabilizing operations. But a better marijuana company doesn't automatically make a better marijuana stock.
Until the company demonstrates consistent profitability and positive free cash flow, I'd view the recent progress as encouraging rather than conclusive. For now, there are simply too many execution risks to call the stock a confident buy.
In the latest close session, Canopy Growth Corporation (CGC - Free Report) was down 1.04% at $0.95. This move lagged the S&P 500's daily loss of 0.45%. Meanwhile, the Dow experienced a drop of 0.25%, and the technology-dominated Nasdaq saw a decrease of 1.16%.
Shares of the company witnessed a loss of 5.88% over the previous month, trailing the performance of the Medical sector with its gain of 6.33%, and the S&P 500's gain of 2.14%.
The investment community will be paying close attention to the earnings performance of Canopy Growth Corporation in its upcoming release. It is anticipated that the company will report an EPS of -$0.04, marking a 71.43% rise compared to the same quarter of the previous year. Meanwhile, the latest consensus estimate predicts the revenue to be $58.52 million, indicating a 12.25% increase compared to the same quarter of the previous year.
For the annual period, the Zacks Consensus Estimates anticipate earnings of -$0.11 per share and a revenue of $243.57 million, signifying shifts of +75.56% and +18.26%, respectively, from the last year.
Investors should also note any recent changes to analyst estimates for Canopy Growth Corporation. These recent revisions tend to reflect the evolving nature of short-term business trends. Consequently, upward revisions in estimates express analysts' positivity towards the business operations and its ability to generate profits.
Empirical research indicates that these revisions in estimates have a direct correlation with impending stock price performance. We developed the Zacks Rank to capitalize on this phenomenon. Our system takes these estimate changes into account and delivers a clear, actionable rating model.
The Zacks Rank system, stretching from #1 (Strong Buy) to #5 (Strong Sell), has a noteworthy track record of outperforming, validated by third-party audits, with stocks rated #1 producing an average annual return of +25% since the year 1988. The Zacks Consensus EPS estimate has moved 13.79% lower within the past month. As of now, Canopy Growth Corporation holds a Zacks Rank of #3 (Hold).
The Medical - Products industry is part of the Medical sector. At present, this industry carries a Zacks Industry Rank of 178, placing it within the bottom 28% of over 250 industries.
The Zacks Industry Rank is ordered from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Don't forget to use Zacks.com to keep track of all these stock-moving metrics, and others, in the upcoming trading sessions.
Investors often get excited about stock splits. They bring a stock down to a lower price, which can lead to more trading and potentially a rally. A reverse stock split, however, can have the opposite effect. A company normally deploys this when its share price has fallen so low that it needs to consolidate shares to get it back above $1, to ensure it satisfies the stock exchange's requirements.
Canopy Growth (CGC 1.04%) is no stranger to reverse stock splits, having done one a few years ago. Now, however, with its share price declining sharply and back below the $1 mark, the inevitable question looms: Is another reverse stock split on the horizon for the cannabis company?
Image source: Getty Images.
Will Canopy Growth announce a reverse stock split this year? Whether or not Canopy Growth deploys another reverse stock split will ultimately depend on how its share price does. That's because if it wants to remain listed on the Nasdaq exchange, it needs to get back up to at least the $1 mark -- if it gets to 30 consecutive business days of being below that threshold, it'll receive a notification from the exchange, at which point, it'll have 180 days to regain compliance. Thus, a reverse stock split may not necessarily happen this year, but it remains a distinct possibility within the next 12 months.
The last time Canopy Growth did a reverse split was in December 2023, when it did a 1-for-10 reverse split. Unfortunately, with the stock falling by around 80% since then, it's trading below $1 yet again.
Today's Change
(
-1.04
%) $
-0.01
Current Price
$
0.95
Financials matter more than reverse splits A stock split doesn't affect an investor's overall holdings and position in a company. If there's a reverse split, an investor would simply own fewer shares but at a higher average price. All it symbolizes is that a stock has been doing so poorly that it needs a reverse split to boost its share price, likely to meet the exchange's $1 minimum requirement.
The big picture for investors is that Canopy Growth just doesn't have a strong business. It's continually incurring losses, and its growth prospects aren't exactly promising. That's why the stock is in trouble and continues to fall: it's not a quality investment to hold on to. Regardless of whether another reverse split is coming or not, the safest option is likely to stay far away from this troubled stock, as there are plenty of better growth stocks to choose from.
Canopy Growth (CGC +5.41%) may have surged during the spring's rescheduling rally for marijuana stocks, but since then, this popular cannabis legalization play has coughed back these gains, falling back below $1 per share as I write this.
Nevertheless, one sell-side analyst remains very bullish on the company's prospects. But I'm not convinced. While the analyst provides substance to back his bull case, his argument doesn't quite explain how Canopy can deliver triple-digit percentage gains from here.
Image source: Getty Images.
Canopy Growth and the aggressive price target Currently, the average analyst price target for Canopy Growth is $1.22 per share, about 27% above its U.S. share price as I write this. An outlier of a price target paints a completely different picture of Canopy Growth and its prospects. In a June 16 research note, Roth Capital Partners' Bill Kirk reiterated his buy rating and per-share price target of 5 Canadian dollars on Canopy Growth.
Today's Change
(
5.41
%) $
0.05
Current Price
$
1.00
That's about four times the current price of Canopy's shares listed on the Toronto Stock Exchange (TSX). In his update, the analyst noted that, if not for one-time expenses, Canopy Growth would have "produced a record adjusted EBITDA" (earnings before interest, taxes, depreciation, and amortization) during its recently completed fiscal fourth quarter. Kirk also cited improved market share, further cost-reduction efforts, and other positives, such as the prospect of reduced future shareholder dilution.
Take this outlier forecast with a grain of salt Kirk may lay out a strong argument, but it's difficult to see how his forecast will translate into a 4x surge for Canopy shares. His FY2027 estimates call for modest revenue growth of around 5.1% and for adjusted EBITDA to remain negative, though near breakeven. Meeting or beating this may be enough to send the stock modestly higher, to the aforementioned median price target, but not fourfold.
Perhaps Kirk's forecast anticipates faster-than-expected progress in U.S. federal marijuana legalization efforts. Still, there are other marijuana stocks with stronger fundamentals and legalization catalysts, such as already profitable U.S.-based cannabis companies licensed at the state level. If you're bullish on the trend, consider these names instead, and take Kirk's optimistic forecast on Canopy Growth with a grain of salt.
Thomas Niel has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.
Canopy Growth Corporation (CGC - Free Report) closed the most recent trading day at $0.95, moving -4.45% from the previous trading session. The stock's performance was behind the S&P 500's daily gain of 0.79%. On the other hand, the Dow registered a gain of 0.26%, and the technology-centric Nasdaq increased by 1.52%.
Shares of the company witnessed a loss of 7.94% over the previous month, trailing the performance of the Medical sector with its gain of 7.53%, and the S&P 500's loss of 1.82%.
Investors will be eagerly watching for the performance of Canopy Growth Corporation in its upcoming earnings disclosure. In that report, analysts expect Canopy Growth Corporation to post earnings of -$0.04 per share. This would mark year-over-year growth of 71.43%. In the meantime, our current consensus estimate forecasts the revenue to be $58.52 million, indicating a 12.25% growth compared to the corresponding quarter of the prior year.
In terms of the entire fiscal year, the Zacks Consensus Estimates predict earnings of -$0.11 per share and a revenue of $243.57 million, indicating changes of +75.56% and +18.26%, respectively, from the former year.
It is also important to note the recent changes to analyst estimates for Canopy Growth Corporation. These revisions typically reflect the latest short-term business trends, which can change frequently. Consequently, upward revisions in estimates express analysts' positivity towards the business operations and its ability to generate profits.
Research indicates that these estimate revisions are directly correlated with near-term share price momentum. To benefit from this, we have developed the Zacks Rank, a proprietary model which takes these estimate changes into account and provides an actionable rating system.
Ranging from #1 (Strong Buy) to #5 (Strong Sell), the Zacks Rank system has a proven, outside-audited track record of outperformance, with #1 stocks returning an average of +25% annually since 1988. The Zacks Consensus EPS estimate has moved 13.79% lower within the past month. Canopy Growth Corporation is currently a Zacks Rank #3 (Hold).
The Medical - Products industry is part of the Medical sector. This industry currently has a Zacks Industry Rank of 180, which puts it in the bottom 27% of all 250+ industries.
The strength of our individual industry groups is measured by the Zacks Industry Rank, which is calculated based on the average Zacks Rank of the individual stocks within these groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Be sure to follow all of these stock-moving metrics, and many more, on Zacks.com.
Companies try to highlight the best news when they report earnings. That's to be expected, but you need to go into earnings season knowing you have read beyond the headlines. Canopy Growth (CGC +2.31%) reported huge growth in its medical marijuana business, which saw revenues increase 27% in the fourth quarter of fiscal 2026 and 17% for the full fiscal year. The rest of the business was a bit more mixed.
The good news and the less-than-good news There's no question that Canopy Growth's medical marijuana business is doing well right now. It is also worth noting that the company recently bought MTL Cannabis, a move that should solidify its already strong position in the Canadian medical marijuana market. The strong growth in medical marijuana revenues highlights why the company is leaning into this division.
Image source: Getty Images.
The problem is that this isn't the company's only business. Its recreational marijuana business increased revenue by 20% in fiscal 2026, but the fourth quarter saw only a 1% increase. While the company attributes the full-year growth to "growth in infused PRJ offerings and new All-In-One vaporizers launched early in the fiscal year," the fourth quarter's 1% revenue growth suggests it ended the year on a weak note. That hints this division's outlook may not be as robust as the full-year growth suggests.
Meanwhile, the company's international cannabis sales rose 68% in the quarter, but fell 7% year over year. Supply chain issues were highlighted as a problem earlier in the year. Once again, the outlook is less clear than investors may like. And then there's the Storz & Bickel vaporizer business, which saw sales decline 14% for both the full fiscal year and in the fourth quarter.
Not enough good news to make Canopy Growth a buy It is likely to require more than one strong division for Wall Street to get excited about Canopy Growth again. But there's still some more bad news to consider. Notably, the company's gross margin fell four percentage points in the fourth quarter and six percentage points for the full fiscal year.
Today's Change
(
2.31
%) $
0.02
Current Price
$
0.93
Not surprisingly, Canopy Growth reported negative earnings again in fiscal 2026. In fact, it hasn't reported positive earnings since it went public, more than a decade ago. Now add in the fact that it recapitalized its balance sheet in fiscal 2026, exchanging shares for debt, and most investors should probably watch from the sidelines.
Could Canopy Growth's stock rally from here? Sure. But with only one business clearly performing well, only the most aggressive investors should probably bet on this penny stock having a sustained rally.
Reuben Gregg Brewer has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.
Canopy Growth Corporation (CGC - Free Report) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review some of the factors that might affect the near-term performance of the stock.
Over the past month, shares of this company have returned -13.9%, compared to the Zacks S&P 500 composite's -1.4% change. During this period, the Zacks Medical - Products industry, which Canopy Growth falls in, has lost 1.1%. The key question now is: What could be the stock's future direction?
While media releases or rumors about a substantial change in a company's business prospects usually make its stock 'trending' and lead to an immediate price change, there are always some fundamental facts that eventually dominate the buy-and-hold decision-making.
Revisions to Earnings EstimatesHere at Zacks, we prioritize appraising the change in the projection of a company's future earnings over anything else. That's because we believe the present value of its future stream of earnings is what determines the fair value for its stock.
Our analysis is essentially based on how sell-side analysts covering the stock are revising their earnings estimates to take the latest business trends into account. When earnings estimates for a company go up, the fair value for its stock goes up as well. And when a stock's fair value is higher than its current market price, investors tend to buy the stock, resulting in its price moving upward. Because of this, empirical studies indicate a strong correlation between trends in earnings estimate revisions and short-term stock price movements.
For the current quarter, Canopy Growth is expected to post a loss of $0.04 per share, indicating a change of +71.4% from the year-ago quarter. The Zacks Consensus Estimate has changed -266.7% over the last 30 days.
For the current fiscal year, the consensus earnings estimate of -$0.11 points to a change of +75.6% from the prior year. Over the last 30 days, this estimate has changed -13.8%.
For the next fiscal year, the consensus earnings estimate of $0.09 indicates a change of +18.2% from what Canopy Growth is expected to report a year ago. Over the past month, the estimate has changed +80%.
Having a strong externally audited track record, our proprietary stock rating tool, the Zacks Rank, offers a more conclusive picture of a stock's price direction in the near term, since it effectively harnesses the power of earnings estimate revisions. Due to the size of the recent change in the consensus estimate, along with three other factors related to earnings estimates, Canopy Growth is rated Zacks Rank #3 (Hold).
The chart below shows the evolution of the company's forward 12-month consensus EPS estimate:
12 Month EPS
Projected Revenue GrowthWhile earnings growth is arguably the most superior indicator of a company's financial health, nothing happens as such if a business isn't able to grow its revenues. After all, it's nearly impossible for a company to increase its earnings for an extended period without increasing its revenues. So, it's important to know a company's potential revenue growth.
For Canopy Growth, the consensus sales estimate for the current quarter of $58.52 million indicates a year-over-year change of +12.3%. For the current and next fiscal years, $243.57 million and $266.23 million estimates indicate +18.3% and +9.3% changes, respectively.
Last Reported Results and Surprise HistoryCanopy Growth reported revenues of $51.94 million in the last reported quarter, representing a year-over-year change of +14.7%. EPS of -$0.17 for the same period compares with -$0.94 a year ago.
Compared to the Zacks Consensus Estimate of $53.26 million, the reported revenues represent a surprise of -2.47%. The EPS surprise was -183.33%.
Over the last four quarters, Canopy Growth surpassed consensus EPS estimates two times. The company topped consensus revenue estimates two times over this period.
ValuationWithout considering a stock's valuation, no investment decision can be efficient. In predicting a stock's future price performance, it's crucial to determine whether its current price correctly reflects the intrinsic value of the underlying business and the company's growth prospects.
Comparing the current value of a company's valuation multiples, such as its price-to-earnings (P/E), price-to-sales (P/S), and price-to-cash flow (P/CF), to its own historical values helps ascertain whether its stock is fairly valued, overvalued, or undervalued, whereas comparing the company relative to its peers on these parameters gives a good sense of how reasonable its stock price is.
The Zacks Value Style Score (part of the Zacks Style Scores system), which pays close attention to both traditional and unconventional valuation metrics to grade stocks from A to F (an A is better than a B; a B is better than a C; and so on), is pretty helpful in identifying whether a stock is overvalued, rightly valued, or temporarily undervalued.
Canopy Growth is graded F on this front, indicating that it is trading at a premium to its peers. Click here to see the values of some of the valuation metrics that have driven this grade.
Bottom LineThe facts discussed here and much other information on Zacks.com might help determine whether or not it's worthwhile paying attention to the market buzz about Canopy Growth. However, its Zacks Rank #3 does suggest that it may perform in line with the broader market in the near term.
In the latest trading session, Canopy Growth Corporation (CGC - Free Report) closed at $0.96, marking a -1.04% move from the previous day. The stock's change was less than the S&P 500's daily loss of 0.37%. Meanwhile, the Dow experienced a rise of 0.29%, and the technology-dominated Nasdaq saw a decrease of 1.33%.
The company's stock has dropped by 7% in the past month, falling short of the Medical sector's gain of 1.49% and the S&P 500's gain of 2.02%.
The investment community will be closely monitoring the performance of Canopy Growth Corporation in its forthcoming earnings report. In that report, analysts expect Canopy Growth Corporation to post earnings of -$0.04 per share. This would mark year-over-year growth of 71.43%. At the same time, our most recent consensus estimate is projecting a revenue of $58.52 million, reflecting a 12.25% rise from the equivalent quarter last year.
Looking at the full year, the Zacks Consensus Estimates suggest analysts are expecting earnings of -$0.11 per share and revenue of $243.57 million. These totals would mark changes of +75.56% and +18.26%, respectively, from last year.
Any recent changes to analyst estimates for Canopy Growth Corporation should also be noted by investors. These revisions help to show the ever-changing nature of near-term business trends. Therefore, positive revisions in estimates convey analysts' confidence in the business performance and profit potential.
Based on our research, we believe these estimate revisions are directly related to near-term stock moves. To benefit from this, we have developed the Zacks Rank, a proprietary model which takes these estimate changes into account and provides an actionable rating system.
Ranging from #1 (Strong Buy) to #5 (Strong Sell), the Zacks Rank system has a proven, outside-audited track record of outperformance, with #1 stocks returning an average of +25% annually since 1988. Over the past month, the Zacks Consensus EPS estimate has shifted 13.79% downward. At present, Canopy Growth Corporation boasts a Zacks Rank of #3 (Hold).
The Medical - Products industry is part of the Medical sector. This industry currently has a Zacks Industry Rank of 164, which puts it in the bottom 33% of all 250+ industries.
The Zacks Industry Rank assesses the vigor of our specific industry groups by computing the average Zacks Rank of the individual stocks incorporated in the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
You can find more information on all of these metrics, and much more, on Zacks.com.
Canopy Growth (CGC 2.53%) just reported its results for the fourth quarter of fiscal 2026 (ended March 31), and the cannabis retailer appears to be stabilizing after a few turbulent years, as it improves its balance sheet while targeting key acquisitions.
Looking five years ahead, Canopy's trajectory suggests a transformation from a recovering Canadian producer into a highly streamlined, cash-flow-positive leader across global medical, adult-use, and specialized vaporizer markets.
It's worth noting that the stock has struggled and is down more than 14% this year and more than 33% during the past year.
Image source: Getty Images.
Phase 1: Near-term profitability and operational improvements The immediate priority for Canopy Growth is achieving positive adjusted earnings before interest, taxes, depreciation, and amortization (EBITDA), a target the executive team said it expects to hit during fiscal 2027. In fiscal 2026, the company showed financial discipline, trimming free cash outflow from 176.6 million Canadian dollars ($126.3 million) to CA$69.1 million and cutting its full-year net loss by 49%. That's a great start, but the company will need to continue that for the next two years to become profitable.
The CA$125 million integration of MTL Cannabis, completed in March, positions Canopy as Canada's top medical cannabis company by revenue. MTL gives Canopy a stronger presence in Quebec, the No. 2 cannabis market in Canada. While the first half of fiscal year 2027 will bear the lingering integration costs and inventory adjustments, as shown by its CA$10.7 million in fourth-quarter inventory charges, the second half of fiscal 2027 should see margin expansion.
The company expects growth in its premium medical lines, such as Spectrum Reserve, as well as in adult-use innovations, including high-THC flower and All-In-One vaporizers.
Today's Change
(
-2.53
%) $
-0.02
Current Price
$
0.96
Phase 2: International expansion and the U.S. market catalyst By years three and four, Canopy's primary growth engine will shift decisively from Canada to international territories, specifically Europe and the U.S.
In Europe, Canopy is already has strong tailwinds, highlighted by an impressive 68% growth in international cannabis net revenue in the fourth quarter, following the resolution of historical supply chain constraints. Germany's steady regulatory liberalizations and Europe's expanding acceptance of medical cannabis present an enormous long-term opportunity. Canopy intends to duplicate its dominant Canadian medical framework, driven by insured patient growth and extensive product assortments, across key European medical channels.
At the same time, the company's structural destiny relies heavily on the U.S. Through its non-controlling interest in Canopy USA, the company has insulated its balance sheet while maintaining direct operational exposure to state-legal U.S. markets. Canopy USA's planned ecosystem, including the finalized acquisitions of high-performing brands such as Jetty and Wana Wellness, is set up to scale at the outset of federal policy shifts.
As the U.S. proceeds with the historic shift of medical cannabis from Schedule I -- the most dangerous category -- to Schedule III under the Controlled Substances Act, Canopy USA will trigger full operational integration. This change lets the parent company capitalize on multistate distribution, optimize tax structures under Internal Revenue Code 280E, and aggressively deploy its Canadian intellectual property across U.S. borders.
Phase 3: The mature five-year horizon By year five, Canopy Growth's corporate profile will look radically different from the debt-laden entity of the early 2020s, and it will have significantly cut total long-term debt during the previous five years. Backed by the $131.3 million net cash cushion secured during its strategic January 2026 recapitalization, the company will have fully exited its capital-preservation phase.
The Storz & Bickel vaporizer segment, despite experiencing a temporary 14% revenue contraction in 2026 due to inflation and U.S. import tariffs, will reemerge as a premium consumer tech pillar. Innovation pipelines like the Veazy portable vaporizer line will capture the accessible, tech-driven consumer base, while gross margins will rebound as supply chains stabilize and global trade tariffs normalize.
Cultivation will be largely asset-light, leveraging contracted flower networks such as MTL Cannabis to keep capital expenditures low. Revenue streams will be globally diversified, with Canada serving as a steady, highly optimized cash generator, while Europe and Canopy USA drive rapid top-line growth.
Comeback in Canada Canopy Growth is positioned to operate as a highly integrated, multinational cannabis and device powerhouse five years from now.
There are risk factors to consider, including inflation, shifting regulatory timelines, and intense brand competition that could lead to additional price declines. However, by swapping crippling debt for a positive cash position and pivoting from raw cultivation volume to premium, medical-first consumer brands, Canopy has secured the flexibility required to lead the Canadian and, perhaps, global market.
Key Takeaways CGC framed fiscal 2026 as a reset built on leaner costs, a stronger balance sheet and growth.MTL integration is central, with CGC already executing $6M of targeted $10M annualized synergies.CGC expects fiscal 2027 revenue growth, better margins, lower costs and positive adjusted EBITDA. Canopy Growth Corporation (CGC - Free Report) used its fourth-quarter call to argue that fiscal 2026 was a reset year, with management emphasizing a leaner cost base, a stronger balance sheet and a clearer growth agenda anchored in medical cannabis and Europe.
The setup matters because the quarter itself was uneven. CGC reported a loss of 17 cents per share, wider than the Zacks Consensus Estimate of a loss of 6 cents. Revenues of $51.9 million also missed the consensus mark of $53.3 million by 2.5%.
CGC Makes the Reset Its Main MessageChief executive officer Luc Mongeau described fiscal 2026 as a defining year in which Canopy streamlined operations, reallocated resources and reset the cost structure. He said those actions were beginning to show up in the business and should have a larger impact in fiscal 2027.
Mongeau also tied that reset to a recapitalization that stabilized liquidity and extended debt maturities to 2031. He presented the stronger balance sheet as a way to reduce risk while giving the company more flexibility to pursue growth opportunities.
The press release supported that framing. Canopy ended fiscal 2026 with C$364.7 million in cash and a net cash position of C$131.3 million compared with net debt of C$172.6 million a year earlier.
Canopy Growth Puts MTL at the CenterCanopy made the MTL Cannabis acquisition the central strategic theme of the call. Mongeau said the deal established the company as Canada’s leading medical cannabis business by revenue and added cultivation expertise that should help improve product quality and consistency across the network.
Management said integration has moved quickly. Mongeau told analysts the company is already executing on C$6 million of a targeted C$10 million in annualized cost synergies, while also using Canopy’s distribution network to broaden MTL’s reach, including Germany.
That synergy story went beyond cost cuts. In response to Alliance Global Partners, Mongeau said it is still early, but Canopy expects better flower quality from the combined cultivation base to support growth in both Canadian recreational cannabis and Europe.
CGC Sees Growth in Medical and EuropeFourth-quarter net revenues rose 10% year over year to C$71.2 million, with cannabis revenues up 20% to C$54.5 million. The best-performing areas were Canada medical and international cannabis, which management repeatedly highlighted as the clearest proof that the strategy is gaining traction.
Canada medical revenues increased 27% in the quarter to C$25.3 million, helped by growth in insured patients and a broader assortment. For the full year, Canada medical revenues rose 18%, and adult-use cannabis revenues increased 20%.
Europe was another focal point. Mongeau said Canopy had fixed supply chain issues that hurt earlier results, and international cannabis revenues climbed 68% in the quarter to C$8.6 million. He added that momentum continued into the first quarter of fiscal 2027 and that the company is targeting U.K. expansion this year.
Canopy Growth Argues Margins Are Improving Beneath ChargesChief accounting officer and CFO Thomas Stewart acknowledged that reported profitability was pressured by acquisition-related charges. Cannabis gross margin was 7% in the quarter, weighed down by C$10.7 million of inventory-related charges tied to the MTL transaction and portfolio rationalization.
Stewart’s main rebuttal was adjusted gross margin. Excluding acquisition-related charges, adjusted gross margin for the cannabis segment improved to 26% from 12% a year ago, which he said better reflects the underlying earnings power of the business as integration progresses.
The same argument extended to EBITDA. Adjusted EBITDA loss narrowed to C$6.3 million from C$9.2 million a year earlier, and Stewart said the company would have been closer to breakeven without the inventory charges.
CGC Q&A Highlights the Real HeadwindsThe toughest analyst questioning centered on Veterans Affairs reimbursement changes in Canada medical. Asked by Canaccord Genuity and Zuanic & Associates, Stewart said the company expects pressure on revenues, even as it uses pricing, product mix and retention efforts to protect EBITDA and gross margin.
That was one of the clearest caution points on the call. Stewart said Canopy is seeing positive early fiscal 2027 momentum in medical, but it will be difficult to maintain the same growth level seen in fiscal 2026, and getting back to flat year-over-year performance in Canadian medical will be challenging.
Analysts also pushed on U.S. strategy, but management stayed disciplined. Mongeau said near-term priorities remain Canada and international markets, while Stewart said broader benefits in the U.S. depend on uplisting potential for plant-touching businesses.
Canopy Growth Leaves a Narrower 2027 AgendaThe forward message was focused. The press release said fiscal 2027 should bring net revenue growth, meaningful gross margin improvement and lower operating expense, with positive adjusted EBITDA expected during the year and larger gains weighted to the second half.
Mongeau’s closing comments matched that outlook. He pointed to Canadian medical leadership, more room for adult-use share gains and stronger execution in Germany and Poland as the company’s clearest priorities coming out of the quarter.
The broader takeaway from the call was that Canopy is no longer presenting itself as a story built on optionality alone. Management is trying to show that restructuring, balance sheet repair and MTL integration can translate into more durable operating improvement in fiscal 2027.
Zacks Signals Remain MixedCGC carries a Zacks Rank #3 (Hold). Under the Zacks framework, that points to a more balanced near-term outlook than a Zacks Rank #1 (Strong Buy) or 2 (Buy), while still allowing investors to monitor the stock rather than dismiss it outright. You can see the complete list of today’s Zacks #1 Rank stocks here.
Its Style Scores are mixed, with an F for Value, A for Growth, B for Momentum and a VGM Score of B. That combination suggests stronger growth and momentum characteristics than valuation support. After the quarter’s wider-than-expected loss and revenue miss, the Zacks Rank can still change as earnings estimate revisions adjust following the results.
Analyst’s Disclosure: I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.
Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.
Canopy Growth Corporation (TSX:WEED, NYSE:CGC) reported a narrower quarterly loss and double-digit full-year revenue growth on Monday, as the Canadian cannabis company cited the acquisition of MTL Cannabis and a strategic recapitalization as key drivers of its turnaround effort.
The company posted an adjusted loss per share of $0.29 for its fiscal fourth quarter, missing analyst estimates, though the result represented a 71% improvement from the $1.01 loss in the same period a year earlier.
Revenue came in at $51.95 million, up 13.6% from $45.75 million a year ago, but also fell short of expectations.
For the full fiscal year ended March 31, 2026, Canopy said net revenue in its Canada adult-use cannabis segment grew 20%, while Canada medical revenue rose 18%.
The company completed its acquisition of MTL Cannabis during the fiscal year, a deal it said positions Canopy as Canada's leading medical cannabis company by revenue. Canopy also closed a strategic recapitalization in January 2026 that left it with $131.3 million in net cash at fiscal year-end.
CEO Luc Mongeau said the company used the year to reset operations and lay groundwork for expansion, with Europe emerging as a key target market.
"As the leading medical cannabis business in Canada by revenue, we are well positioned to extend that leadership into Europe," Mongeau said, describing the region as representing "enormous long-term opportunity."
Chief Financial Officer Tom Stewart pointed to balance sheet improvements as a risk-reduction measure that also expands the company's strategic options.
Canopy said it expects net revenue growth across the business in fiscal 2027 and projected that improvements in cultivation practices will contribute to meaningful gross margin gains. The company is targeting positive adjusted EBITDA for the fiscal year, though it cautioned that MTL Cannabis integration activities in the first half of the year mean stronger year-over-year improvements are expected in the second half.
Canopy Growth Corporation (WEED:CA) Q4 2026 Earnings Call June 15, 2026 10:00 AM EDT
Company Participants
Luc Mongeau - CEO & Director
Thomas Stewart - Chief Accounting Officer & CFO
Conference Call Participants
Kenric Tyghe - Canaccord Genuity Corp., Research Division
Aaron Grey - Alliance Global Partners, Research Division
William Kirk - ROTH Capital Partners, LLC, Research Division
Brenna Cunnington - ATB Cormark Capital Markets Inc., Research Division
Pablo Zuanic - Zuanic & Associates
Presentation
Operator
Good morning. My name is Joanna, and I will be your conference operator today. I would like to welcome you to Canopy Growth's Fourth Quarter Fiscal 2026 Financial Results Conference Call. [Operator Instructions]
I will now turn the call over to [ John Vinsek ], Investor Relations. John, you may begin the conference call.
Unknown Executive
Good morning, and thank you for joining us. On our call today, we have Canopy Growth's Chief Executive Officer, Luc Mongeau; and Chief Financial Officer, Tom Stewart.
Prior to the opening of financial markets today, Canopy Growth issued a news release announcing the financial results for its fourth quarter and fiscal year ended March 31, 2026. The news release and financial statements have been filed on EDGAR and SEDAR and will be available on the website under the Investors tab.
Before we begin, I would like to remind you that our discussion during the call will include forward-looking statements that are based on management's current views and assumptions, and that this discussion is qualified in its entirety by the cautionary note regarding forward-looking statements included at the end of the news release issued today. Please review today's earnings release and Canopy's reports filed with the SEC and SEDAR for various factors that could cause actual results to differ materially from projections.
In addition, reconciliations between any non-GAAP measures to their closest
The 2026 Cannabis Wildcard: How Tax Reform Could Reset Stock ValuationsCanopy Growth NASDAQ: CGC reported higher fiscal fourth-quarter revenue and said it entered fiscal 2027 with a stronger balance sheet following a year of restructuring, cost cuts and the acquisition of MTL Cannabis.
On the company’s earnings call, Chief Executive Officer Luc Mongeau described fiscal 2026 as “a defining year” for Canopy Growth, saying the company streamlined its operations, reset its cost base and reallocated resources toward areas it sees as offering stronger long-term returns.
Get Canopy Growth alerts:
Constellation Brands: A Fallen Star or a Hidden Value Play?“These actions are now beginning to show up in the business,” Mongeau said. He cited full-year net revenue growth of 20% in Canada adult-use cannabis and 18% in Canada medical cannabis, along with what he called improved execution across the company’s platform.
Fourth-quarter revenue rises 10% Chief Financial Officer Tom Stewart said Canopy reported net revenue of CAD 71.2 million in the fourth quarter of fiscal 2026, up 10% from the same quarter a year earlier. Cannabis net revenue was CAD 54.5 million, an increase of 20% year over year.
Profit from the Green Wave: Top Cannabis Stocks to WatchThe company’s Canada medical cannabis business delivered CAD 25.3 million in fourth-quarter revenue, up 27% from a year earlier and marking what Stewart called another record quarter. He said the growth was driven by continued expansion in insured patient registrations and efforts to improve the service experience for medical consumers.
International cannabis revenue was CAD 8.6 million in the quarter, up 68% year over year. Stewart said the increase was largely driven by growth in Poland and Germany, where supply chain improvements helped deliver another quarter of growth.
For the full fiscal year, Mongeau said total net revenue increased 6% to CAD 285 million, driven by growth in the Canadian medical and adult-use businesses. He said Canada medical posted positive year-over-year growth in all four quarters, supported by a larger product assortment and increased order sizes as Canopy expanded its insured customer base.
MTL Cannabis integration begins Mongeau called Canopy’s acquisition of MTL Cannabis the “defining milestone” of the year, saying the transaction established Canopy as the leading Canadian medical cannabis business by revenue. MTL had been part of Canopy for two months at the time of the call.
The company is already executing on CAD 6 million of a targeted CAD 10 million in annualized cost synergies, Mongeau said. Stewart said the savings include the elimination of MTL public company costs, headcount reductions and the rationalization of redundant facilities. Canopy expects to reach its CAD 10 million run-rate savings target within 18 months of the transaction closing.
Stewart said Canopy has decided to close its cultivation facility in Kelowna, British Columbia, as it focuses on scaling cultivation capacity at its GMP-certified Kincardine facility and MTL’s facilities in Quebec.
Mongeau said the benefits of the MTL deal extend beyond cost savings, noting that Canopy is using its distribution platform to expand the reach of MTL products, including a recently announced launch of MTL strains in Germany. He also said MTL’s cultivation capabilities are being shared more broadly across Canopy’s network.
Margins affected by acquisition-related inventory charges Canopy’s cannabis gross margin in the fourth quarter was CAD 3.7 million, or 7% of net revenue. Stewart said the margin was below the company’s typical range primarily because of CAD 10.7 million in inventory-related charges tied to the MTL acquisition.
As part of the integration, Canopy conducted a review of the combined inventory and product portfolio and chose to reduce redundant and overlapping inventory, Stewart said. The company also recognized costs associated with the accounting step-up on acquired inventory balances.
Excluding acquisition-related charges, Stewart said adjusted gross margin for the cannabis segment was 26% in the fourth quarter, compared with 12% in the prior-year period.
The company reported an adjusted EBITDA loss of CAD 6 million in the fourth quarter, a CAD 3 million improvement from the prior year but higher than the CAD 3 million loss in the third quarter. Stewart said that absent the inventory charges, Canopy would have shown sequential improvement and moved “significantly closer” to adjusted EBITDA breakeven.
Stewart said Canopy remains confident in reaching positive adjusted EBITDA during fiscal 2027, citing expectations for continued revenue growth and lower costs.
Balance sheet strengthens after recapitalization Canopy ended fiscal 2026 with CAD 365 million in cash after completing the MTL acquisition. Stewart said total debt stood at CAD 234 million, resulting in a net cash position of CAD 131 million.
Compared with the end of fiscal 2025, Stewart said Canopy improved its financial position by CAD 304 million, moving from net debt of CAD 173 million to net cash of CAD 131 million. He said the company now has greater financial capacity to support growth and potential inorganic opportunities.
Stewart also said Canopy did not make sales under its at-the-market program during the fourth quarter, but may use the program opportunistically in fiscal 2027 to support strategic priorities if they arise.
Fiscal 2027 priorities include Canada, Europe and profitability Looking ahead, Mongeau said Canopy is focused on capital allocation toward higher-return opportunities, cost management and execution. He said the company’s priorities include accelerating growth in Canadian recreational cannabis and Europe while pursuing positive EBITDA and positive cash flow.
In Canada adult-use cannabis, Mongeau said Canopy returned to growth in fiscal 2026 as net revenue increased 20%. He said growth was driven by innovation in categories such as infused pre-rolls, vape and THC flower. He added that May 2026 market share data showed Canopy had improved from the No. 8 overall ranking to No. 6.
Mongeau said the company’s longer-term aspiration is to become a top-three player in Canadian recreational cannabis. He pointed to opportunities in flower, pre-rolls, infused pre-rolls and vape, including the 510 vape category, where he said Canopy is “almost absent.”
In Europe, Mongeau said Canopy had reset operations to improve the flower supply chain, after earlier challenges in fiscal 2026. He said the company delivered strong sequential growth in the last two quarters and expects Europe to remain an important focus. Canopy is targeting expansion into the U.K. during fiscal 2027.
Storz & Bickel revenue declined for the year due to challenges in the U.S. and Germany, Mongeau said. He noted that the launch of the VEAZY vaporizer helped sales in a new category focused on affordability and portability. The company is now focused on cost optimization and a refreshed commercial approach in the U.S.
During the question-and-answer portion of the call, analysts asked about changes to Veterans Affairs Canada reimbursement, U.S. regulatory developments and Canopy’s cash balance. Stewart said reimbursement changes are expected to be a headwind for the Canadian medical business, but Canopy is taking pricing, product mix and retention actions intended to mitigate the effect on revenue, margin and adjusted EBITDA.
On the U.S., Mongeau said Canopy’s near-term focus remains Canada and international markets, where he said the company can create value more immediately. Still, he said Canopy is encouraged by U.S. regulatory changes and believes its investments, including Jetty, its affiliation with the Claybourne infused pre-roll brand and its investment in TerrAscend, position it to benefit as regulations evolve.
About Canopy Growth NASDAQ: CGCCanopy Growth Corporation is a leading Canadian cannabis company engaged in the production, distribution and sale of both medical and recreational cannabis products. Headquartered in Smiths Falls, Ontario, the company cultivates a diversified portfolio of offerings that includes dried flower, pre-rolled joints, oils, softgel capsules and edibles. Canopy Growth also markets derivative products such as beverages and wellness formulations under a range of brands, aiming to serve both patient and adult-use markets.
The company operates through multiple subsidiaries, including Tweed Inc, Spectrum Therapeutics and Tokyo Smoke, each targeting distinct consumer segments.
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to [email protected].
Should You Invest $1,000 in Canopy Growth Right Now?Before you consider Canopy Growth, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Canopy Growth wasn't on the list.
While Canopy Growth currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat's analysts have just released their top five short plays for June 2026. Learn which stocks have the most short interest and how to trade them. Click the link to see which companies made the list.
Canopy Growth Corporation (TSX:WEED, NYSE:CGC) reported a narrower quarterly loss and double-digit full-year revenue growth on Monday, as the Canadian cannabis company cited the acquisition of MTL Cannabis and a strategic recapitalization as key drivers of its turnaround effort.
The company posted an adjusted loss per share of $0.29 for its fiscal fourth quarter, missing analyst estimates, though the result represented a 71% improvement from the $1.01 loss in the same period a year earlier.
Revenue came in at $51.95 million, up 13.6% from $45.75 million a year ago, but also fell short of expectations.
For the full fiscal year ended March 31, 2026, Canopy said net revenue in its Canada adult-use cannabis segment grew 20%, while Canada medical revenue rose 18%.
The company completed its acquisition of MTL Cannabis during the fiscal year, a deal it said positions Canopy as Canada's leading medical cannabis company by revenue. Canopy also closed a strategic recapitalization in January 2026 that left it with $131.3 million in net cash at fiscal year-end.
CEO Luc Mongeau said the company used the year to reset operations and lay groundwork for expansion, with Europe emerging as a key target market.
"As the leading medical cannabis business in Canada by revenue, we are well positioned to extend that leadership into Europe," Mongeau said, describing the region as representing "enormous long-term opportunity."
Chief Financial Officer Tom Stewart pointed to balance sheet improvements as a risk-reduction measure that also expands the company's strategic options.
Canopy said it expects net revenue growth across the business in fiscal 2027 and projected that improvements in cultivation practices will contribute to meaningful gross margin gains. The company is targeting positive adjusted EBITDA for the fiscal year, though it cautioned that MTL Cannabis integration activities in the first half of the year mean stronger year-over-year improvements are expected in the second half.
SMITHS FALLS, Ontario--(BUSINESS WIRE)--Canopy Growth Corporation ("Canopy Growth" or the "Company") (TSX: WEED) (Nasdaq: CGC) today announced its financial results for the three months ended March 31, 2026 ("Q4 FY2026") and the fiscal year ended March 31, 2026 ("FY2026"). All financial information in this press release is reported in Canadian dollars, unless otherwise indicated. “In fiscal 2026, we reset the business, laid a disciplined foundation, and made deliberate investments, including ac.
Canopy Growth Corporation (CGC - Free Report) came out with a quarterly loss of $0.17 per share versus the Zacks Consensus Estimate of a loss of $0.06. This compares to a loss of $0.94 per share a year ago. These figures are adjusted for non-recurring items.
This quarterly report represents an earnings surprise of -199.82%. A quarter ago, it was expected that this company would post a loss of $0.03 per share when it actually produced a loss of $0.1, delivering a surprise of -233.33%.
Over the last four quarters, the company has surpassed consensus EPS estimates two times.
Canopy Growth, which belongs to the Zacks Medical - Products industry, posted revenues of $51.94 million for the quarter ended March 2026, missing the Zacks Consensus Estimate by 2.47%. This compares to year-ago revenues of $45.3 million. The company has topped consensus revenue estimates two times over the last four quarters.
The sustainability of the stock's immediate price movement based on the recently-released numbers and future earnings expectations will mostly depend on management's commentary on the earnings call.
Canopy Growth shares have lost about 12.3% since the beginning of the year versus the S&P 500's gain of 8.6%.
What's Next for Canopy Growth?While Canopy Growth has underperformed the market so far this year, the question that comes to investors' minds is: what's next for the stock?
There are no easy answers to this key question, but one reliable measure that can help investors address this is the company's earnings outlook. Not only does this include current consensus earnings expectations for the coming quarter(s), but also how these expectations have changed lately.
Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions. Investors can track such revisions by themselves or rely on a tried-and-tested rating tool like the Zacks Rank, which has an impressive track record of harnessing the power of earnings estimate revisions.
Ahead of this earnings release, the estimate revisions trend for Canopy Growth was mixed. While the magnitude and direction of estimate revisions could change following the company's just-released earnings report, the current status translates into a Zacks Rank #3 (Hold) for the stock. So, the shares are expected to perform in line with the market in the near future. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here.
It will be interesting to see how estimates for the coming quarters and the current fiscal year change in the days ahead. The current consensus EPS estimate is -$0.01 on $65.13 million in revenues for the coming quarter and -$0.11 on $278.96 million in revenues for the current fiscal year.
Investors should be mindful of the fact that the outlook for the industry can have a material impact on the performance of the stock as well. In terms of the Zacks Industry Rank, Medical - Products is currently in the bottom 30% of the 250 plus Zacks industries. Our research shows that the top 50% of the Zacks-ranked industries outperform the bottom 50% by a factor of more than 2 to 1.
Nurix Therapeutics, Inc. (NRIX - Free Report) , another stock in the broader Zacks Medical sector, has yet to report results for the quarter ended May 2026.
This company is expected to post quarterly loss of $0.73 per share in its upcoming report, which represents a year-over-year change of -40.4%. The consensus EPS estimate for the quarter has been revised 1.8% higher over the last 30 days to the current level.
Nurix Therapeutics, Inc.'s revenues are expected to be $14.3 million, down 67.5% from the year-ago quarter.
After years of restructuring, dilution, asset sales, and losses, investors remain sharply divided on whether Canopy Growth Corporation (CGC 0.49%) is finally stabilizing or simply extending a long decline.
Indeed, the next 12 months will likely provide an answer to that question.
Here are three realistic scenarios for where Canopy Growth stock could go next.
Image source: Getty Images.
Scenario 1: Canopy finally stabilizes This is the bullish case. Canopy has spent the past several years cutting costs, restructuring operations, and narrowing losses. In fiscal Q3 2026 (ended Dec. 31), the company reported revenue of $75 million Canadian dollars ($55 million) while adjusted earnings before interest, taxes, depreciation and amortization (EBITDA) losses narrowed to about CA$3 million, marking its third consecutive quarter of improvement.
This isn't trivial because profitability has always been the central issue surrounding Canopy Growth.
The company also ended September 2025 with about CA$298 million in cash and cash equivalents, exceeding debt balances by roughly CA$70 million after making $50 million in debt prepayments.
Operationally, Canopy is finally showing pockets of growth again. Canada adult-use cannabis revenue increased 8% year over year in Q3, while medical cannabis revenue rose 15%. Management now believes the company can achieve positive adjusted EBITDA during fiscal 2027.
If Canopy can sustain revenue growth while maintaining cost discipline, investors may begin treating the company less like a distressed cannabis operator and more like a turnaround story.
Of course, that would require continued margin improvement, stable Canadian cannabis pricing, and stronger cash flow trends.
Under that scenario, the stock could recover meaningfully from current depressed levels.
Scenario 2: The company survives, but the stock goes nowhere This may be the most realistic outcome. Despite operational improvements, Canopy still faces structural problems that haven't disappeared.
The Canadian cannabis market remains oversupplied and intensely competitive. Pricing pressure continues to hurt margins across the industry, while regulatory delays limit meaningful U.S. expansion opportunities.
Meanwhile, Wall Street analysts still expect Canopy Growth to remain unprofitable for the foreseeable future, with some forecasts projecting only modest or little changed revenue growth over the next fiscal year.
That creates a difficult setup for shareholders. Canopy may ultimately survive financially without necessarily generating the type of earnings growth needed to justify a sustained stock rally.
This scenario would likely involve periodic dilution, continued restructuring, slow revenue growth, and ongoing volatility tied to cannabis legalization developments.
In other words, the company survives, but shareholders are stuck with dead money.
Today's Change
(
-0.49
%) $
-0.01
Current Price
$
1.00
Scenario 3: Another major breakdown This is the bearish case. Canopy has already undergone multiple restructurings, but the company still operates in an industry with weak pricing power, limited profitability, and uncertain regulation.
If Canadian cannabis pricing deteriorates further or consumer demand weakens, Canopy could quickly find itself back under financial pressure despite recent balance-sheet improvements. The company has still reported significant losses in fiscal 2026, including a Q3 net loss of about CA$63 million.
The cannabis sector also remains heavily dependent on investor sentiment. If broader market conditions weaken or capital becomes more expensive again, speculative cannabis stocks, many of which are still in prominent marijuana exchange-traded funds (ETFs), could face another major sell-off similar to previous industry downturns.
There's also execution risk. Canopy continues betting heavily on product innovation, premium brands, medical cannabis expansion, and international markets. But international cannabis sales actually declined sharply during parts of fiscal 2026 because of European supply chain problems.
If those operational challenges persist while revenue growth stalls, the market could begin to question whether the turnaround is truly sustainable.
The bottom line is simple: Canopy Growth long ago stopped being the hypergrowth marijuana stock story. Today, it's a restructuring and survival story.
The company has improved its balance sheet, narrowed losses, and stabilized parts of its business. But profitability remains elusive, the cannabis industry is saturated, and investor confidence remains fragile.
Top Canadian Cannabis Stocks to Watch in May 2026 Canadian cannabis stocks remain active in May 2026. Investors continue watching the sector for growth opportunities and reform catalysts. In addition, many traders expect future federal progress in the United States. That possibility has increased interest across the entire cannabis market. Recent headlines surrounding possible cannabis rescheduling also boosted momentum in leading names.
At the same time, volatility remains high in the cannabis sector. Therefore, traders should continue using technical analysis and proper risk management. Many cannabis stocks still trade well below previous highs. However, improving revenue trends and international expansion continue to support long-term optimism. Three Canadian cannabis companies stand out this month. These companies are Tilray Brands, Canopy Growth, and Village Farms International.
[Read More] Top Marijuana Companies Building Momentum In 2026
3 Canadian Marijuana Stocks Investors Are Watching Right Now Tilray Brands (NASDAQ: TLRY) Canopy Growth (NASDAQ: CGC) Village Farms International (NASDAQ: VFF) Tilray Brands (NASDAQ: TLRY) Tilray remains one of the largest cannabis companies in Canada. The company also has a growing international footprint. In addition, Tilray operates across cannabis, beverages, wellness products, and pharmaceutical distribution. That diversification continues to set it apart from many competitors. Tilray currently holds leading market share positions across several cannabis categories in Canada.
The company’s largest United States presence comes from its beverage alcohol operations. Tilray owns several craft beer brands across multiple states. Meanwhile, the company continues positioning itself for future U.S. cannabis legalization. Tilray does not currently operate U.S. dispensaries directly because of federal restrictions. However, the company maintains strategic exposure through partnerships and acquisitions. Investors continue watching Tilray closely because of its broad international operations. Furthermore, Tilray remains active throughout Europe’s medical cannabis market. The company has also expanded into hemp wellness and pharmaceutical distribution businesses. That diversification may help reduce sector volatility over time. As a result, many investors still consider Tilray one of the leading Canadian cannabis stocks.
Tilray recently reported strong fiscal third-quarter 2026 results. The company posted quarterly revenue of approximately $207 million. That figure represented an 11% year-over-year increase. Gross profit also improved during the quarter. In addition, Tilray reported expanding cannabis revenue and strong international growth.
International cannabis revenue increased sharply compared to last year. The company also significantly reduced overall net losses. Furthermore, management continues focusing on operational efficiency and cost reductions. Tilray’s distribution business also contributed positively during the quarter. However, the beverage segment still faced some pressure. Rising competition within the cannabis industry also remains a challenge. Despite those issues, investors reacted positively to improving growth trends. Analysts continue to closely monitor future profitability and U.S. reform developments. Tilray shares remain volatile, but many traders still watch the stock closely for momentum opportunities. Therefore, TLRY remains a top Canadian cannabis stock to watch in May 2026.
[Read More] 3 Top Picks For Marijuana Stocks Investors To See Profits In 2026
Canopy Growth (NASDAQ: CGC) Canopy Growth remains one of the most recognized cannabis companies worldwide. The company built its reputation during the early cannabis boom years. Today, Canopy continues restructuring operations while focusing on efficiency and premium cannabis products. The company maintains strong medical and adult-use cannabis operations across Canada. In addition, Canopy continues expanding internationally through medical cannabis distribution.
Canopy’s largest United States exposure comes through strategic partnerships and cannabis-related investments. The company has positioned itself carefully for future U.S. legalization opportunities. However, Canopy does not currently operate active U.S. dispensaries directly. Instead, management continues focusing on brand development and international expansion. Canopy’s Canadian cannabis business remains its core operation today. The company continues emphasizing premium flower, pre-rolls, and vaporizer products. In addition, Canopy has significantly strengthened its medical cannabis business. Medical cannabis sales in Canada improved because of rising insured patient demand. Investors continue watching Canopy because of its strong brand recognition. Furthermore, the company still maintains one of the most recognized names in the global cannabis sector.
Canopy recently released its fiscal 2026 quarterly financial results. The company reported improving cannabis revenue trends across several business segments. Canadian medical cannabis revenue increased compared to last year. Adult-use cannabis revenue also improved because of stronger product demand.
However, profitability challenges remain a major concern for investors. Gross margins declined compared to prior periods. Operating losses also remained elevated during the quarter. Nevertheless, management continues to implement restructuring and cost reduction initiatives. The company also maintains a significant cash reserve position. That liquidity may help support operations during the ongoing turnaround effort. Investors continue watching whether Canopy can achieve sustainable profitability in future quarters. In addition, future U.S. cannabis reform could provide another catalyst for the stock. CGC remains highly speculative, but traders continue monitoring the company closely. Therefore, Canopy Growth stays on many cannabis watchlists for May 2026.
[Read More] Top Canadian Cannabis Penny Stocks to Watch This Month
Village Farms International (NASDAQ: VFF) Village Farms International continues to gain attention within the cannabis industry. The company originally built its business through greenhouse agriculture operations. Today, Village Farms operates one of Canada’s leading cannabis cultivation businesses through Pure Sunfarms. In addition, the company maintains strong international export operations. Village Farms has also expanded into medical cannabis opportunities across Europe and other markets.
The company’s largest United States presence still comes from agricultural operations rather than cannabis dispensaries. Village Farms currently does not operate U.S. cannabis dispensaries directly. However, management continues preparing for possible future U.S. legalization opportunities. Investors continue to focus on Village Farms due to its greenhouse production expertise. Furthermore, the company benefits from relatively efficient cultivation costs compared to many competitors. Pure Sunfarms continues to hold strong market share positions within Canada’s cannabis market. The company has also aggressively expanded international cannabis exports over the last year. That international growth continues to support investor optimism. As a result, Village Farms has become one of the more closely watched Canadian cannabis companies.
Village Farms recently reported strong first-quarter 2026 financial results. The company generated record quarterly cannabis sales during the period. Total sales increased approximately 27% year over year. Cannabis revenue growth also exceeded many analyst expectations. Gross margins improved significantly compared to prior periods.
Importantly, Village Farms also reported positive earnings from continuing operations. That achievement marked another profitable quarter for the company. International cannabis exports increased sharply during the quarter as well. Management also discussed potential opportunities from future U.S. cannabis reform. In addition, the company continues strengthening its balance sheet and operational efficiency. Investors responded positively to the improving profitability trends. Many traders now view Village Farms as one of the stronger financial performers within the cannabis sector. Therefore, VFF remains one of the top Canadian cannabis stocks to watch in May 2026.
SMITHS FALLS, Ontario--(BUSINESS WIRE)--Canopy Growth Corporation (“Canopy Growth” or the “Company”) (TSX: WEED) (Nasdaq: CGC) expects to release its financial results for the quarter and fiscal year ended March 31, 2026 before financial markets open on June 15, 2026. The Company also announced it plans to file restated financial results for the fiscal years ended March 31, 2025 and March 31, 2024 and to certain of the interim periods therein (the “Refiling”), in conjunction with its filing of.
In the latest close session, Canopy Growth Corporation (CGC - Free Report) was down 5.55% at $0.98. The stock trailed the S&P 500, which registered a daily loss of 0.07%. Elsewhere, the Dow saw an upswing of 0.32%, while the tech-heavy Nasdaq depreciated by 0.51%.
Coming into today, shares of the company had lost 8.77% in the past month. In that same time, the Medical sector lost 2.17%, while the S&P 500 gained 5.58%.
Analysts and investors alike will be keeping a close eye on the performance of Canopy Growth Corporation in its upcoming earnings disclosure. The company's earnings report is set to go public on May 29, 2026. In that report, analysts expect Canopy Growth Corporation to post earnings of -$0.06 per share. This would mark year-over-year growth of 93.62%. Meanwhile, the Zacks Consensus Estimate for revenue is projecting net sales of $53.26 million, up 17.56% from the year-ago period.
For the full year, the Zacks Consensus Estimates project earnings of -$0.36 per share and a revenue of $210.58 million, demonstrating changes of +87.92% and +8.94%, respectively, from the preceding year.
Investors should also note any recent changes to analyst estimates for Canopy Growth Corporation. These latest adjustments often mirror the shifting dynamics of short-term business patterns. With this in mind, we can consider positive estimate revisions a sign of optimism about the business outlook.
Our research shows that these estimate changes are directly correlated with near-term stock prices. Investors can capitalize on this by using the Zacks Rank. This model considers these estimate changes and provides a simple, actionable rating system.
The Zacks Rank system, running from #1 (Strong Buy) to #5 (Strong Sell), holds an admirable track record of superior performance, independently audited, with #1 stocks contributing an average annual return of +25% since 1988. Over the past month, there's been no change in the Zacks Consensus EPS estimate. Canopy Growth Corporation is currently a Zacks Rank #2 (Buy).
The Medical - Products industry is part of the Medical sector. This industry, currently bearing a Zacks Industry Rank of 156, finds itself in the bottom 37% echelons of all 250+ industries.
The Zacks Industry Rank is ordered from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
You can find more information on all of these metrics, and much more, on Zacks.com.
Canopy Growth Corporation (CGC - Free Report) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look at some of the facts that could shape the stock's performance in the near term.
Shares of this company have returned -13.2% over the past month versus the Zacks S&P 500 composite's +3.3% change. The Zacks Medical - Products industry, to which Canopy Growth belongs, has lost 11.1% over this period. Now the key question is: Where could the stock be headed in the near term?
Although media reports or rumors about a significant change in a company's business prospects usually cause its stock to trend and lead to an immediate price change, there are always certain fundamental factors that ultimately drive the buy-and-hold decision.
Revisions to Earnings EstimatesHere at Zacks, we prioritize appraising the change in the projection of a company's future earnings over anything else. That's because we believe the present value of its future stream of earnings is what determines the fair value for its stock.
We essentially look at how sell-side analysts covering the stock are revising their earnings estimates to reflect the impact of the latest business trends. And if earnings estimates go up for a company, the fair value for its stock goes up. A higher fair value than the current market price drives investors' interest in buying the stock, leading to its price moving higher. This is why empirical research shows a strong correlation between trends in earnings estimate revisions and near-term stock price movements.
For the current quarter, Canopy Growth is expected to post a loss of $0.06 per share, indicating a change of +93.6% from the year-ago quarter. The Zacks Consensus Estimate remained unchanged over the last 30 days.
The consensus earnings estimate of -$0.36 for the current fiscal year indicates a year-over-year change of +87.9%. This estimate has remained unchanged over the last 30 days.
For the next fiscal year, the consensus earnings estimate of $0.11 indicates a change of +69.4% from what Canopy Growth is expected to report a year ago. Over the past month, the estimate has remained unchanged.
With an impressive externally audited track record, our proprietary stock rating tool -- the Zacks Rank -- is a more conclusive indicator of a stock's near-term price performance, as it effectively harnesses the power of earnings estimate revisions. The size of the recent change in the consensus estimate, along with three other factors related to earnings estimates, has resulted in a Zacks Rank #3 (Hold) for Canopy Growth.
The chart below shows the evolution of the company's forward 12-month consensus EPS estimate:
12 Month EPS
Projected Revenue GrowthEven though a company's earnings growth is arguably the best indicator of its financial health, nothing much happens if it cannot raise its revenues. It's almost impossible for a company to grow its earnings without growing its revenue for long periods. Therefore, knowing a company's potential revenue growth is crucial.
For Canopy Growth, the consensus sales estimate for the current quarter of $53.26 million indicates a year-over-year change of +17.6%. For the current and next fiscal years, $210.58 million and $278.96 million estimates indicate +8.9% and +32.5% changes, respectively.
Last Reported Results and Surprise HistoryCanopy Growth reported revenues of $53.47 million in the last reported quarter, representing a year-over-year change of +0.1%. EPS of -$0.1 for the same period compares with -$0.76 a year ago.
Compared to the Zacks Consensus Estimate of $50.59 million, the reported revenues represent a surprise of +5.7%. The EPS surprise was -233.33%.
Over the last four quarters, Canopy Growth surpassed consensus EPS estimates two times. The company topped consensus revenue estimates two times over this period.
ValuationNo investment decision can be efficient without considering a stock's valuation. Whether a stock's current price rightly reflects the intrinsic value of the underlying business and the company's growth prospects is an essential determinant of its future price performance.
Comparing the current value of a company's valuation multiples, such as its price-to-earnings (P/E), price-to-sales (P/S), and price-to-cash flow (P/CF), to its own historical values helps ascertain whether its stock is fairly valued, overvalued, or undervalued, whereas comparing the company relative to its peers on these parameters gives a good sense of how reasonable its stock price is.
The Zacks Value Style Score (part of the Zacks Style Scores system), which pays close attention to both traditional and unconventional valuation metrics to grade stocks from A to F (an A is better than a B; a B is better than a C; and so on), is pretty helpful in identifying whether a stock is overvalued, rightly valued, or temporarily undervalued.
Canopy Growth is graded D on this front, indicating that it is trading at a premium to its peers. Click here to see the values of some of the valuation metrics that have driven this grade.
ConclusionThe facts discussed here and much other information on Zacks.com might help determine whether or not it's worthwhile paying attention to the market buzz about Canopy Growth. However, its Zacks Rank #3 does suggest that it may perform in line with the broader market in the near term.
For anyone who has observed Canopy Growth (CGC 0.49%) during the past few years, it won't be shocking to learn that the marijuana company's stock is diving in May. Since the start of the month, it's down by more than 12% as of this writing, against the nearly 2% gain of the bellwether S&P 500 index.
Today's Change
(
-0.49
%) $
-0.01
Current Price
$
1.00
Years of net losses and struggles with sales growth have taken their toll on investor sentiment. Yet there are Canopy Growth bulls in the investing community that point to a recent acquisition, in particular, as a cause for hope.
I'm not buying that view, and I'm not buying the company's stock. Read on for why.
A business full of headaches The company's home country, Canada, began full legalization of recreational weed in 2018. That was also the golden era of cannabis companies, as investors flocked to weed stocks at the dawn of this seemingly glorious new market.
Except that the market wasn't so impressive. Regulatory bottlenecks in Canada hampered its development, while persistent gray- and black-market competition and oversupply left the company constantly struggling. At least it wasn't alone in that respect; north-of-the-border peers like Tilray Brands have also had a tough time prospering in such an environment.
The vast and wealthy U.S. market -- where Canopy Growth has a presence through its Canopy USA affiliate -- is always tantalizing. This is more promise than reality, however. De facto legalization is frustratingly piecemeal, and reform has occurred in fits and starts, at best.
So, in both its home country and here, Canopy Growth remains challenged to eke out any growth and reduce the flow of red ink on the bottom line. Over the years, it has tried numerous times to shore up its finances with fresh secondary-share issues, but the dilution has been significant for existing shareholders and has driven away potential investors.
CGC Shares Outstanding data by YCharts.
Going the acquisition route In March, Canopy Growth closed its acquisition of Quebec-based medical marijuana company MTL Cannabis. The notable factor in this deal is that MTL is an outlier: It's a pure-play weed company that has posted more than a few bottom-line profits.
On that basis alone, investors were excited about its potential to improve Canopy Growth's financials. I'm not as impressed; I don't think the deal -- paid with a mix of cash and stock and valued at $125 million Canadian dollars ($91 million) -- will be a game changer for the buyer.
In MTL's four reported quarters leading up to the acquisition, its gross product revenue ranged from just under C$15 million to nearly C$19 million. In two of the four quarters, it posted net income, with those profits coming in just shy of C$490,000 and slightly more than C$1 million.
Image Source: Getty Images.
Meanwhile, if we look at Canopy Growth's latest quarterly results, the pot company's top line was C$54.5 million, and its net loss (which, to give the company its due, was considerably narrower than the prior-year shortfall) amounted to almost C$45.8 million.
So even when MTL posts bottom-line profits, these surely won't do much to mitigate the chronic and deep losses of its new parent.
Not so high on the sector Given that, I predict more dilutive share issues for Canopy Growth, as this is the company's classic go-to reaction to financial stress. I don't see many accretive deals for it in the future -- its resources are limited, and it's doubtful there are scores of (at least occasionally) profitable operators in the market ripe for acquisition.
I also don't envision the numerous challenges in Canada dissipating anytime soon, if ever. The U.S. might never enact a complete national legalization of recreational marijuana. Yet even if it does, the country has more than its share of domestic weed companies that would pounce on any meaningful legalization move.
Plus, those U.S. companies just got a break from the federal government, which last month rescheduled medical pot to a more lenient status. This change included the elimination of the Internal Revenue Service's Section 280E rule -- a move that drastically eased the tax burden on the country's multistate operators.
So, in sum, there are numerous compelling reasons to stay away from Canopy Growth stock specifically, and -- save for a very few clever companies -- the broader marijuana sector generally. There are better places to park our precious investment money.
Key Takeaways Canopy Growth posted 8% adult-use sales growth and 15% medical cannabis revenue growth in Q3.CGC expects MTL Cannabis acquisition to improve margins and expand medical cannabis reach.Canopy Growth targets positive adjusted EBITDA in fiscal 2027 amid pricing and tariff headwinds. Canopy Growth Corporation (CGC - Free Report) is back in focus as marijuana reclassification efforts revive investor interest in cannabis stocks. While the regulatory shift has improved sentiment across the sector, investors are increasingly separating companies with improving fundamentals from those still struggling to establish a sustainable business model.
CGC has recently taken steps to strengthen its operations through cost cuts, balance-sheet improvements and the acquisition of MTL Cannabis. However, persistent margin pressure and execution risks continue to cloud the company’s long-term outlook.
Let’s take a closer look at the company’s fundamentals to determine whether the stock deserves a place in investors’ portfolios following the marijuana reclassification push.
CGC Strengthens Medical Cannabis Push Amid Turnaround EffortsCanopy Growth is increasingly leaning on its Canadian medical cannabis franchise and product innovation strategy as it works toward a sustainable turnaround. The company’s latest quarterly performance highlighted improving traction in core cannabis operations, supported by stronger patient demand and continued momentum in select adult-use categories.
During the third quarter of fiscal 2026 (year ending March 2026), Canadian adult-use cannabis sales increased 8% year over year, benefiting from demand for infused pre-rolls and vape products across brands like Tweed, Claybourne and 7ACRES. On the medical side, revenues advanced 15%, aided by growth in insured patient registrations, higher order volumes and ongoing improvements in fulfillment and service levels.
Canopy has also expanded its medical cannabis portfolio through its Spectrum Therapeutics division by launching new 30- and 90-pack softgels and additional dosing formats. This reflects the company’s broader effort to deepen patient engagement and strengthen recurring medical revenue streams.
Beyond organic growth, the recently completed MTL Cannabis acquisition could further strengthen Canopy’s position in medical cannabis while improving cultivation efficiency and product quality. Management expects the deal to support margin expansion, provide access to premium flower supply and enhance the company’s ability to serve international markets, particularly Europe.
The company is also working to stabilize its international cannabis operations after prior supply-chain disruptions affected European sales. Management noted that improving flower availability, expanding strain selection and ongoing EU GMP progress at its Smiths Falls facility are expected to support sequential improvement through fiscal 2027.
At the same time, challenges remain. Cannabis gross margins declined year over year due to a weaker international mix and pricing pressures, while Storz & Bickel continues to face macroeconomic and tariff-related headwinds despite recent product launches. Canopy also continues to navigate reimbursement-related uncertainty in the Canadian medical market.
Still, management remains focused on cost discipline and expects the company to achieve positive adjusted EBITDA at some point during fiscal 2027.
Cutthroat Competition in the Cannabis SpaceCanopy Growth competes in an overcrowded market against large operators like Aurora Cannabis (ACB - Free Report) and SNDL Inc. (SNDL - Free Report) . Like CGC, these companies maintain a sizable presence in the Canadian cannabis market.
Aurora has increasingly prioritized higher-margin international medical cannabis markets, particularly Europe, while SNDL continues to expand its vertically integrated cannabis and retail operations through acquisitions and broad product offerings. These strategies are intensifying competition across key growth categories, including medical cannabis, vapes and premium flower.
As cannabis operators continue to pursue profitability and international expansion, Canopy will likely need to sustain product innovation, improve margins and successfully integrate MTL Cannabis to strengthen its competitive positioning.
CGC Stock Performance and EstimatesYear to date, shares of Canopy Growth have lost 6% compared with the industry’s 23% decline.
Image Source: Zacks Investment Research
Bottom-line estimates for fiscal 2026 and 2027 have remained stable in the past 60 days.
Image Source: Zacks Investment Research
How to Play CGC Stock?While marijuana reclassification efforts have improved sentiment toward cannabis stocks, Canopy Growth Corporation continues to face profitability and execution challenges despite recent operational improvements.
Investors should note that marijuana reclassification is still evolving gradually rather than through a sweeping federal transformation. Even if reforms progress, several restrictions surrounding U.S. cannabis businesses are likely to remain in place.
We would also like to remind investors that Canopy Growth does not directly operate cannabis businesses in the United States due to federal restrictions and exchange-listing considerations. The company maintains strategic exposure to the market through Canopy USA, which holds interests in Acreage Holdings, Wana Brands and Jetty.
Although CGC is targeting positive adjusted EBITDA in fiscal 2027, persistent margin pressure, reimbursement uncertainty and intense competition remain key risks. Given these factors, investors may want to hold off on initiating or adding to positions until Canopy Growth reports its fiscal fourth-quarter results. A cautious approach toward this Zacks Rank #3 (Hold) stock remains warranted.
You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Most investors should probably avoid Canopy Growth (CGC 0.49%). There was early enthusiasm on Wall Street about the opportunity ahead for marijuana companies, but the reality didn't live up to the excitement. At this point, Canopy Growth has been losing money for years, and the shares have declined so much that it is a penny stock.
And now the company is going to restate two years' worth of earnings. If you are a Canopy Growth shareholder, or are thinking of becoming one, here is what you need to know right now.
Image source: Getty Images.
The marijuana business is still competitive One of the big problems with the marijuana sector is that too many competitors jumped in too quickly. That resulted in intense competition in a market that was still young and evolving. Despite ongoing legalization, the result of this competition has been weak financial performance for companies like Canopy Growth. It is hardly alone, noting that Tilray Brands (TLRY 2.73%), Cronos Group (CRON 2.54%), and Aurora Cannabis (ACB 1.14%) have all been struggling to achieve sustainably profitability.
Worse, legal marijuana companies aren't the only competitive threat. The illicit sale of marijuana didn't stop just because the drug has become increasingly legal to sell. And since legal sellers such as Canopy Growth have to face regulatory costs and taxes, they are being undercut on price by illegally sold marijuana.
Only more aggressive investors should consider investing in a sector that remains complex and evolving. Further, money-losing penny stocks are risky, too, so Canopy Growth has multiple high-risk features to consider before hitting the buy button.
Canopy Growth is restating its results And now the company has announced it will restate its financial results over the past two years. Investors would be entirely justified in being concerned about a company's internal controls following a restatement, particularly if the company was losing money and the stock was trading in penny-stock land.
Today's Change
(
-0.49
%) $
-0.01
Current Price
$
1.00
Not surprisingly, Canopy Growth's stock fell after the news was released. As investors digested the announcement, however, the stock has recovered. That, too, makes sense, given the explanation for the restatement. According to the company:
During the Company's year-end financial reporting process for the fiscal year ended March 31, 2026, the Company identified a technical non-cash accounting error. The Company determined that certain share-settled warrants with exercise prices denominated in U.S. dollars, first issued during the fiscal year ended March 31, 2024, should have been classified as liabilities rather than equity instruments under applicable accounting standards, given the Company's Canadian dollar functional currency. Accordingly, the Company should have recorded these instruments as liabilities on its consolidated balance sheets and measured them at fair value at each reporting date, with changes in fair value recorded in the consolidated statements of operations and comprehensive loss.
That is a mouthful, but the big story is that these changes aren't expected to impact "revenue, gross margin, operating income/loss and cash flows from operations; Adjusted EBITDA or other key non-GAAP performance metrics used by management and investors; total assets, cash balances, liquidity, or ability to meet obligations or fund operations; compliance with any debt covenants, contractual ratios or borrowing capacity."
When you step back, it appears to be a technical accounting issue that won't negatively impact anything important. And, perhaps even more notable, the company believes the restatement won't impact "the trajectory or narrative of financial performance." In other words, if you bought Canopy Growth before the restatement news, there's probably no reason for you to sell it.
Investors should still tread with caution with Canopy Growth That said, shareholders should pay close attention to the restatement as more information becomes available. The big date is June 15, when Canopy Growth reports fiscal 2026 earnings. Investors considering buying the stock should probably wait to jump aboard until after the restatements are complete, just in case. Most investors, meanwhile, will likely be better off avoiding a money-losing penny stock that is in the middle of a restatement. Until the company is sustainably profitable, the risk/reward profile remains tilted in a worrying direction.
In the latest trading session, Canopy Growth Corporation (CGC - Free Report) closed at $1.07, marking a +1.9% move from the previous day. This move outpaced the S&P 500's daily gain of 0.02%. Elsewhere, the Dow gained 0.36%, while the tech-heavy Nasdaq added 0.07%.
The company's stock has dropped by 8.7% in the past month, falling short of the Medical sector's gain of 2.02% and the S&P 500's gain of 5.12%.
The investment community will be paying close attention to the earnings performance of Canopy Growth Corporation in its upcoming release. The company is slated to reveal its earnings on June 15, 2026. The company's upcoming EPS is projected at -$0.06, signifying a 93.62% increase compared to the same quarter of the previous year. Alongside, our most recent consensus estimate is anticipating revenue of $53.26 million, indicating a 17.56% upward movement from the same quarter last year.
For the entire fiscal year, the Zacks Consensus Estimates are projecting earnings of -$0.36 per share and a revenue of $210.58 million, representing changes of +87.92% and +8.94%, respectively, from the prior year.
Investors should also pay attention to any latest changes in analyst estimates for Canopy Growth Corporation. These revisions typically reflect the latest short-term business trends, which can change frequently. Consequently, upward revisions in estimates express analysts' positivity towards the business operations and its ability to generate profits.
Empirical research indicates that these revisions in estimates have a direct correlation with impending stock price performance. To take advantage of this, we've established the Zacks Rank, an exclusive model that considers these estimated changes and delivers an operational rating system.
The Zacks Rank system, spanning from #1 (Strong Buy) to #5 (Strong Sell), boasts an impressive track record of outperformance, audited externally, with #1 ranked stocks yielding an average annual return of +25% since 1988. Within the past 30 days, our consensus EPS projection remained stagnant. Currently, Canopy Growth Corporation is carrying a Zacks Rank of #3 (Hold).
The Medical - Products industry is part of the Medical sector. This group has a Zacks Industry Rank of 160, putting it in the bottom 35% of all 250+ industries.
The Zacks Industry Rank evaluates the power of our distinct industry groups by determining the average Zacks Rank of the individual stocks forming the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
You can find more information on all of these metrics, and much more, on Zacks.com.
Canopy Growth Relaunches Tweed Brand in Germany with New MTL Cannabis Strain Lineup, Marking First International Release following Acquisition Canopy Growth Corporation (“Canopy Growth” or the “Company”) (TSX: WEED) (Nasdaq: CGC) today announced the relaunch of the Tweed brand in the German medical market, alongside the introduction of three cannabis strains developed by MTL Cannabis Corp. (“MTL”), a wholly-owned subsidiary of the Company. The dual milestone represents the Company’s first international product release following its recent acquisition of MTL.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260529712694/en/
Pablo's Revenge
The Tweed brand relaunch – now powered by MTL’s premium genetics – signals the Company’s commitment to leveraging the full equity of its legacy brand in key international markets and comes as Germany’s medical cannabis market continues to expand rapidly, approaching $1 billion in annual value in 20251. The MTL acquisition has enhanced Canopy Growth’s capacity to meet rising demand in key international markets, including Germany, while reintroducing a brand that physicians and patients have come to trust.
"Germany is one of the fastest-growing medical cannabis markets globally, and demand continues to scale rapidly. The relaunch of our Tweed brand is a meaningful moment for us, reflecting both the strength of what we have built, and our commitment to delivering consistent, high-quality cannabis that physicians can prescribe with confidence and patients can rely on as part of their care. We believe the European Union represents a tremendous opportunity for Canopy, and Germany is just the beginning,” said Luc Mongeau, Chief Executive Officer, Canopy Growth.
The initial launch includes three cultivars – Pablo’s Revenge, Dante’z Inferno, and Frost’d Flakes – selected for their quality and consistency. Up to five MTL-derived strains are expected to be introduced in June 2026, with further portfolio expansion planned throughout the year.
The Company also announced today that it has been granted a management cease trade order effective as of May 28, 2026, by its principal regulator, the Ontario Securities Commission under National Policy 12-203 – Management Cease Trade Orders. This follows the Company’s announcement on May 15, 2026 regarding certain non-cash technical errors in the Company’s accounting relating to certain share-settled warrants of the Company with exercise prices denominated in U.S. dollars, first issued during the fiscal year ended March 31, 2024. The Company intends to refile the relevant financial statements (the “Refiling”) in its Annual Report on Form 10-K for the fiscal year ended March 31, 2026, which is expected to be filed with Canadian securities regulators and with the United States Securities and Exchange Commission (the “SEC”) on June 15, 2026 (the “Comprehensive Form 10-K”).
About Canopy Growth
Canopy Growth is a world-leading cannabis company dedicated to unleashing the power of cannabis to improve lives. Its portfolio of owned and licensed brands including Tweed, 7ACRES, DOJA, Deep Space, Deelish, Claybourne, MTL Cannabis, Low Key by MTL and R’belle, as well as category defining Storz & Bickel, delivers innovative products to consumers across Canada and beyond.
Canopy Growth is Canada’s leading provider of medical cannabis services through Canada House Clinics and serves patients online via Abba Medix. The Company also holds unconsolidated, non-controlling interest in Canopy USA, LLC, which provides exposure to the U.S. THC market.
Committed to quality, responsible use, and community, Canopy Growth is shaping a future where cannabis is embraced for its potential to enhance well-being.
For more information visit www.canopygrowth.com
Forward-Looking Statements
This news release contains “forward-looking statements” within the meaning of the United States Private Securities Litigation Reform Act of 1995 and “forward-looking information” within the meaning of applicable Canadian securities legislation. Often, but not always, forward-looking statements and information can be identified by the use of words such as “plans”, “expects” or “does not expect”, “is expected”, “estimates”, “intends”, “anticipates” or “does not anticipate”, or “believes”, or variations of such words and phrases or state that certain actions, events or results “may”, “could”, “would”, “might” or “will” be taken, occur or be achieved. Forward-looking statements or information involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of the Company or its subsidiaries to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements or information contained in this news release. Examples of such statements and uncertainties include statements with respect to the occurrence, timing and expectations relating to further portfolio expansion in European markets including an additional five MTL-derived strains expected to be introduced in 2026; the outstanding work and the planned filing of the Refiling; the expected timing of the filing of the Comprehensive Form 10-K; disclosure of further updates and bi-weekly status reports with respect to the MCTO; the timing, duration and impacts with respect to the MCTO; and expectations for other economic, business, and/or competitive factors.
Risks, uncertainties and other factors involved with forward-looking information or statements could cause actual events, results, performance, prospects and opportunities to differ materially from those expressed or implied by such forward-looking information, including delays in completing the Refiling and the Comprehensive Form 10-K; risks relating to the dilutive impact of the transactions and future resales of Common Shares in the public market, which may negatively affect the stock price of Common Shares; negative operating cash flow; uncertainty of additional financing; use of proceeds; volatility in the price of the Common Shares; risks relating to the overall macroeconomic environment, which may impact customer spending, costs and margins, including tariffs (and related retaliatory measures), the levels of inflation, and interest rates; expectations regarding future investment, growth and expansion of operations; regulatory and licensing risks; changes in general economic, business and political conditions, including changes in the financial and stock markets; legal and regulatory risks inherent in the cannabis industry, including the global regulatory landscape and enforcement related to cannabis; additional dilution; political risks and risks relating to regulatory change, including with respect to reimbursement rates in the medical cannabis market; risks relating to anti-money laundering laws; compliance with extensive government regulation and the interpretation of various laws regulations and policies; public opinion and perception of the cannabis industry; and such other risks contained in the public filings of the Company filed with Canadian securities regulators and available under the Company’s profile on SEDAR+ at www.sedarplus.ca and with the SEC through EDGAR at www.sec.gov/edgar, including under the heading “Risk Factors” in the Company’s annual report on Form 10-K for the fiscal year ended March 31, 2025 and its subsequently filed quarterly reports on Form 10-Q.
In respect of the forward-looking statements and information, the Company has provided such statements and information in reliance on certain assumptions that they believe are reasonable at this time. Although the Company believes that the assumptions and factors used in preparing the forward-looking information or forward-looking statements in this news release are reasonable, undue reliance should not be placed on such information or statements and no assurance can be given that such events will occur in the disclosed time frames or at all. Should one or more of the foregoing risks or uncertainties materialize, or should assumptions underlying the forward-looking information or statements prove incorrect, actual results may vary materially from those described herein as intended, planned, anticipated, believed, estimated or expected. Although the Company has attempted to identify important risks, uncertainties and factors which could cause actual results to differ materially, there may be others that cause results not to be as anticipated, estimated or intended. The forward-looking information and forward-looking statements included in this news release are made as of the date of this news release and the Company does not undertake any obligation to publicly update such forward-looking information or forward-looking statements to reflect new information, subsequent events or otherwise unless required by applicable securities laws.
View source version on businesswire.com: https://www.businesswire.com/news/home/20260529712694/en/
Pablo’s Revenge, Dante’z Inferno, and Frost’d Flakes launched under Tweed brand
Up to five additional strains expected to follow in June 2026
Company targeting rapid growth in Germany’s medical cannabis market
SMITH FALLS, Ontario--(BUSINESS WIRE)--Canopy Growth Corporation (“Canopy Growth” or the “Company”) (TSX: WEED) (Nasdaq: CGC) today announced the relaunch of the Tweed brand in the German medical market, alongside the introduction of three cannabis strains developed by MTL Cannabis Corp. (“MTL”), a wholly-owned subsidiary of the Company. The dual milestone represents the Company’s first international product release following its recent acquisition of MTL.
The Tweed brand relaunch – now powered by MTL’s premium genetics – signals the Company’s commitment to leveraging the full equity of its legacy brand in key international markets and comes as Germany’s medical cannabis market continues to expand rapidly, approaching $1 billion in annual value in 20251. The MTL acquisition has enhanced Canopy Growth’s capacity to meet rising demand in key international markets, including Germany, while reintroducing a brand that physicians and patients have come to trust.
"Germany is one of the fastest-growing medical cannabis markets globally, and demand continues to scale rapidly. The relaunch of our Tweed brand is a meaningful moment for us, reflecting both the strength of what we have built, and our commitment to delivering consistent, high-quality cannabis that physicians can prescribe with confidence and patients can rely on as part of their care. We believe the European Union represents a tremendous opportunity for Canopy, and Germany is just the beginning,” said Luc Mongeau, Chief Executive Officer, Canopy Growth.
The initial launch includes three cultivars – Pablo’s Revenge, Dante’z Inferno, and Frost’d Flakes – selected for their quality and consistency. Up to five MTL-derived strains are expected to be introduced in June 2026, with further portfolio expansion planned throughout the year.
The Company also announced today that it has been granted a management cease trade order effective as of May 28, 2026, by its principal regulator, the Ontario Securities Commission under National Policy 12-203 – Management Cease Trade Orders. This follows the Company’s announcement on May 15, 2026 regarding certain non-cash technical errors in the Company’s accounting relating to certain share-settled warrants of the Company with exercise prices denominated in U.S. dollars, first issued during the fiscal year ended March 31, 2024. The Company intends to refile the relevant financial statements (the “Refiling”) in its Annual Report on Form 10-K for the fiscal year ended March 31, 2026, which is expected to be filed with Canadian securities regulators and with the United States Securities and Exchange Commission (the “SEC”) on June 15, 2026 (the “Comprehensive Form 10-K”).
About Canopy Growth
Canopy Growth is a world-leading cannabis company dedicated to unleashing the power of cannabis to improve lives. Its portfolio of owned and licensed brands including Tweed, 7ACRES, DOJA, Deep Space, Deelish, Claybourne, MTL Cannabis, Low Key by MTL and R’belle, as well as category defining Storz & Bickel, delivers innovative products to consumers across Canada and beyond.
Canopy Growth is Canada’s leading provider of medical cannabis services through Canada House Clinics and serves patients online via Abba Medix. The Company also holds unconsolidated, non-controlling interest in Canopy USA, LLC, which provides exposure to the U.S. THC market.
Committed to quality, responsible use, and community, Canopy Growth is shaping a future where cannabis is embraced for its potential to enhance well-being.
For more information visit www.canopygrowth.com
Forward-Looking Statements
This news release contains “forward-looking statements” within the meaning of the United States Private Securities Litigation Reform Act of 1995 and “forward-looking information” within the meaning of applicable Canadian securities legislation. Often, but not always, forward-looking statements and information can be identified by the use of words such as “plans”, “expects” or “does not expect”, “is expected”, “estimates”, “intends”, “anticipates” or “does not anticipate”, or “believes”, or variations of such words and phrases or state that certain actions, events or results “may”, “could”, “would”, “might” or “will” be taken, occur or be achieved. Forward-looking statements or information involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of the Company or its subsidiaries to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements or information contained in this news release. Examples of such statements and uncertainties include statements with respect to the occurrence, timing and expectations relating to further portfolio expansion in European markets including an additional five MTL-derived strains expected to be introduced in 2026; the outstanding work and the planned filing of the Refiling; the expected timing of the filing of the Comprehensive Form 10-K; disclosure of further updates and bi-weekly status reports with respect to the MCTO; the timing, duration and impacts with respect to the MCTO; and expectations for other economic, business, and/or competitive factors.
Risks, uncertainties and other factors involved with forward-looking information or statements could cause actual events, results, performance, prospects and opportunities to differ materially from those expressed or implied by such forward-looking information, including delays in completing the Refiling and the Comprehensive Form 10-K; risks relating to the dilutive impact of the transactions and future resales of Common Shares in the public market, which may negatively affect the stock price of Common Shares; negative operating cash flow; uncertainty of additional financing; use of proceeds; volatility in the price of the Common Shares; risks relating to the overall macroeconomic environment, which may impact customer spending, costs and margins, including tariffs (and related retaliatory measures), the levels of inflation, and interest rates; expectations regarding future investment, growth and expansion of operations; regulatory and licensing risks; changes in general economic, business and political conditions, including changes in the financial and stock markets; legal and regulatory risks inherent in the cannabis industry, including the global regulatory landscape and enforcement related to cannabis; additional dilution; political risks and risks relating to regulatory change, including with respect to reimbursement rates in the medical cannabis market; risks relating to anti-money laundering laws; compliance with extensive government regulation and the interpretation of various laws regulations and policies; public opinion and perception of the cannabis industry; and such other risks contained in the public filings of the Company filed with Canadian securities regulators and available under the Company’s profile on SEDAR+ at www.sedarplus.ca and with the SEC through EDGAR at www.sec.gov/edgar, including under the heading “Risk Factors” in the Company’s annual report on Form 10-K for the fiscal year ended March 31, 2025 and its subsequently filed quarterly reports on Form 10-Q.
In respect of the forward-looking statements and information, the Company has provided such statements and information in reliance on certain assumptions that they believe are reasonable at this time. Although the Company believes that the assumptions and factors used in preparing the forward-looking information or forward-looking statements in this news release are reasonable, undue reliance should not be placed on such information or statements and no assurance can be given that such events will occur in the disclosed time frames or at all. Should one or more of the foregoing risks or uncertainties materialize, or should assumptions underlying the forward-looking information or statements prove incorrect, actual results may vary materially from those described herein as intended, planned, anticipated, believed, estimated or expected. Although the Company has attempted to identify important risks, uncertainties and factors which could cause actual results to differ materially, there may be others that cause results not to be as anticipated, estimated or intended. The forward-looking information and forward-looking statements included in this news release are made as of the date of this news release and the Company does not undertake any obligation to publicly update such forward-looking information or forward-looking statements to reflect new information, subsequent events or otherwise unless required by applicable securities laws.
Canopy Growth (CGC 0.49%) is no longer the market darling it once was. Shares of the cannabis maker remain down more than 95% from their all-time highs, the company continues to post net losses, and Canada's cannabis industry remains plagued by oversupply, pricing pressure, and intense competition.
That said, if you dig into the numbers, there are signs that the business may finally be stabilizing. This doesn't mean Canopy Growth has completed its turnaround. And no, profitability isn't guaranteed. But several key metrics suggest management's restructuring efforts may finally be gaining traction.
Image source: Getty Images.
Adjusted EBITDA losses have shrunk dramatically One of the biggest challenges facing Canopy over the past several years has been its inability to generate sustainable operating profits. The company has spent years closing cultivation facilities, reducing headcount, exiting non-core businesses, and cutting operating expenses. Certainly, we've heard turnaround promises before, but the financial results are starting to reflect those efforts.
In its most recent quarter, Canopy reported an adjusted EBITDA (earnings before interest, taxes, depreciation, and amortization) loss of approximately $2.17 million. While still negative, that's a dramatic improvement from the much larger losses the company reported just a few years ago, when quarterly adjusted EBITDA losses routinely exceeded tens of millions of dollars.
Management continues targeting positive adjusted EBITDA during fiscal 2027. Whether it achieves that goal remains to be seen, but the trend is moving in the right direction.
An uptick in medical cannabis Another encouraging development is the continued growth of Canopy's medical cannabis business. Medical cannabis revenue from Canada increased 15% year over year, driven by growth in insured patients and larger order sizes.
For Canopy, this isn't trivial. Unlike the Canadian recreational market, which faces heavy discounting and price competition, medical cannabis markets tend to have higher barriers to entry, stronger customer retention, and better pricing dynamics.
This is the result of patients using cannabis to manage ongoing medical conditions, which can lead to recurring purchases and longer-term customer relationships. Medical products are also generally less exposed to the aggressive price compression that has weighed on many recreational cannabis producers.
The balance sheet looks stronger Perhaps the most important number is Canopy's cash position. As of its most recent quarter, the company reported approximately $230 million in cash and cash equivalents. It also completed a roughly US$50 million debt prepayment, reducing future interest expenses and improving overall financial flexibility.
That's not a perfect balance sheet, but it does provide management with additional runway to execute its strategy. The company isn't being forced into a desperate financing situation, which gives it more time to focus on improving operations rather than simply raising capital.
Today's Change
(
-0.49
%) $
-0.01
Current Price
$
1.00
Risks remain Of course, there are still challenges. Canopy is still reporting a quarterly net loss, and the Canadian cannabis market remains oversupplied. Regulatory uncertainty continues to weigh on the broader industry, too. And while U.S. cannabis reform remains a potential catalyst, the timing and scope of any meaningful changes remain difficult to predict.
Competition is also intense. Larger operators and lower-cost producers continue to fight for market share, putting pressure on pricing across the industry.
The bull case The bull case for Canopy isn't based on explosive revenue growth or a sudden industry recovery. It's based on the possibility that the company has finally stopped moving in the wrong direction.
A smaller adjusted EBITDA loss, continued growth in medical cannabis revenue, and a stronger balance sheet don't guarantee success. But they do suggest the business may be getting healthier after years of restructuring.
So if you're willing to accept the risks associated with marijuana stocks, these three numbers provide a reasonable argument that a turnaround may finally be starting.
In the latest close session, Canopy Growth Corporation (CGC - Free Report) was down 1.85% at $1.06. The stock fell short of the S&P 500, which registered a gain of 0.13% for the day. Elsewhere, the Dow gained 0.45%, while the tech-heavy Nasdaq added 0.03%.
The company's stock has dropped by 1.82% in the past month, falling short of the Medical sector's gain of 1.01% and the S&P 500's gain of 5.25%.
The upcoming earnings release of Canopy Growth Corporation will be of great interest to investors. The company's earnings report is expected on June 15, 2026. The company is predicted to post an EPS of -$0.06, indicating a 93.62% growth compared to the equivalent quarter last year. Meanwhile, our latest consensus estimate is calling for revenue of $53.26 million, up 17.56% from the prior-year quarter.
For the entire fiscal year, the Zacks Consensus Estimates are projecting earnings of -$0.36 per share and a revenue of $210.58 million, representing changes of +87.92% and +8.94%, respectively, from the prior year.
Investors should also note any recent changes to analyst estimates for Canopy Growth Corporation. Such recent modifications usually signify the changing landscape of near-term business trends. Consequently, upward revisions in estimates express analysts' positivity towards the business operations and its ability to generate profits.
Our research demonstrates that these adjustments in estimates directly associate with imminent stock price performance. We developed the Zacks Rank to capitalize on this phenomenon. Our system takes these estimate changes into account and delivers a clear, actionable rating model.
The Zacks Rank system, which varies between #1 (Strong Buy) and #5 (Strong Sell), carries an impressive track record of exceeding expectations, confirmed by external audits, with stocks at #1 delivering an average annual return of +25% since 1988. Over the past month, the Zacks Consensus EPS estimate has remained steady. Canopy Growth Corporation presently features a Zacks Rank of #3 (Hold).
The Medical - Products industry is part of the Medical sector. With its current Zacks Industry Rank of 153, this industry ranks in the bottom 38% of all industries, numbering over 250.
The Zacks Industry Rank gauges the strength of our industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Don't forget to use Zacks.com to keep track of all these stock-moving metrics, and others, in the upcoming trading sessions.
Canopy Growth (CGC 0.49%) has had a terrible go of it in the past five years. Despite the cannabis industry experiencing regulatory progress in Canada and elsewhere, the company's financial results have been subpar at best, while it has lost significant market value. Could Canopy Growth bounce back? The pot grower recently made an acquisition it hopes will be the spark it needs to turn things around. Let's find out whether there are brighter days ahead for Canopy Growth following this acquisition.
Image source: Getty Images.
Expanding its reach On March 16, Canopy Growth completed the acquisition of MTL Cannabis, a Canadian company. MTL's portfolio of products and brands included pre-rolls, vape cartridges, dried flower, and more. It also operates in Quebec, the second-largest cannabis market in Canada, where Canopy Growth will now have a stronger presence thanks to the acquisition. According to Canopy Growth, this move makes it the leading medical cannabis company in the country by revenue. However, it wasn't a cheap transaction for Canopy Growth. The total equity value of the deal was about $125 million, but Canopy Growth paid for the transaction in a mix of cash and stock and chose to issue new shares to do so.
Today's Change
(
-0.49
%) $
-0.01
Current Price
$
1.00
Not worth the trouble Canopy Growth has not performed well over the past few years due to challenges in its home country. Even though cannabis is legal in Canada, there remains substantial regulatory oversight that has slowed the market's progress. That's not to mention the oversupply issues stemming from significant competition in Canada. The result has been slow sales growth (at best) and consistent red ink on the bottom line.
CGC Revenue (Annual) data by YCharts
Canopy Growth's buyout of MTL Cannabis isn't the first time it has tried to improve its financial results and market position through an acquisition, but past attempts have had little success. In my view, this one will be no different. Meanwhile, Canopy Growth's issuance of new shares to fund this transaction further dilutes existing shareholders. Perhaps it would be worth it if we could reasonably expect that Canopy Growth's financial results would meaningfully improve as a result.
But beyond an immediate spike in top-line growth from the acquisition, the business's underlying fundamentals might not change much. Further, Canopy Growth is facing other issues. The company recently announced that it had identified accounting errors in several of its past financial statements and now intends to refile. While management stated that this would not affect key metrics such as revenue, gross margins, and net income or losses, it's not a good look, especially for a company struggling on multiple fronts.
So, what's the verdict? Canopy Growth is operating in a challenging-to-navigate industry with uncertain prospects, generates poor financial results, and is forced to significantly dilute existing shareholders for an acquisition that may not move the needle nearly as much as it hopes, given the challenges in Canada. For all those reasons (and more), it's best to avoid this stock.
Canopy Growth Corporation (CGC - Free Report) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to consider some of the key factors that could influence the stock's performance in the near future.
Shares of this company have returned -9.6% over the past month versus the Zacks S&P 500 composite's +4.6% change. The Zacks Medical - Products industry, to which Canopy Growth belongs, has lost 4.3% over this period. Now the key question is: Where could the stock be headed in the near term?
Although media reports or rumors about a significant change in a company's business prospects usually cause its stock to trend and lead to an immediate price change, there are always certain fundamental factors that ultimately drive the buy-and-hold decision.
Revisions to Earnings EstimatesRather than focusing on anything else, we at Zacks prioritize evaluating the change in a company's earnings projection. This is because we believe the fair value for its stock is determined by the present value of its future stream of earnings.
Our analysis is essentially based on how sell-side analysts covering the stock are revising their earnings estimates to take the latest business trends into account. When earnings estimates for a company go up, the fair value for its stock goes up as well. And when a stock's fair value is higher than its current market price, investors tend to buy the stock, resulting in its price moving upward. Because of this, empirical studies indicate a strong correlation between trends in earnings estimate revisions and short-term stock price movements.
For the current quarter, Canopy Growth is expected to post a loss of $0.06 per share, indicating a change of +93.6% from the year-ago quarter. The Zacks Consensus Estimate remained unchanged over the last 30 days.
For the current fiscal year, the consensus earnings estimate of -$0.36 points to a change of +87.9% from the prior year. Over the last 30 days, this estimate has remained unchanged.
For the next fiscal year, the consensus earnings estimate of $0.11 indicates a change of +69.4% from what Canopy Growth is expected to report a year ago. Over the past month, the estimate has remained unchanged.
Having a strong externally audited track record, our proprietary stock rating tool, the Zacks Rank, offers a more conclusive picture of a stock's price direction in the near term, since it effectively harnesses the power of earnings estimate revisions. Due to the size of the recent change in the consensus estimate, along with three other factors related to earnings estimates, Canopy Growth is rated Zacks Rank #3 (Hold).
The chart below shows the evolution of the company's forward 12-month consensus EPS estimate:
12 Month EPS
Revenue Growth ForecastEven though a company's earnings growth is arguably the best indicator of its financial health, nothing much happens if it cannot raise its revenues. It's almost impossible for a company to grow its earnings without growing its revenue for long periods. Therefore, knowing a company's potential revenue growth is crucial.
In the case of Canopy Growth, the consensus sales estimate of $53.26 million for the current quarter points to a year-over-year change of +17.6%. The $210.58 million and $278.96 million estimates for the current and next fiscal years indicate changes of +8.9% and +32.5%, respectively.
Last Reported Results and Surprise HistoryCanopy Growth reported revenues of $53.47 million in the last reported quarter, representing a year-over-year change of +0.1%. EPS of -$0.1 for the same period compares with -$0.76 a year ago.
Compared to the Zacks Consensus Estimate of $50.59 million, the reported revenues represent a surprise of +5.7%. The EPS surprise was -233.33%.
Over the last four quarters, Canopy Growth surpassed consensus EPS estimates two times. The company topped consensus revenue estimates two times over this period.
ValuationWithout considering a stock's valuation, no investment decision can be efficient. In predicting a stock's future price performance, it's crucial to determine whether its current price correctly reflects the intrinsic value of the underlying business and the company's growth prospects.
Comparing the current value of a company's valuation multiples, such as its price-to-earnings (P/E), price-to-sales (P/S), and price-to-cash flow (P/CF), to its own historical values helps ascertain whether its stock is fairly valued, overvalued, or undervalued, whereas comparing the company relative to its peers on these parameters gives a good sense of how reasonable its stock price is.
The Zacks Value Style Score (part of the Zacks Style Scores system), which pays close attention to both traditional and unconventional valuation metrics to grade stocks from A to F (an A is better than a B; a B is better than a C; and so on), is pretty helpful in identifying whether a stock is overvalued, rightly valued, or temporarily undervalued.
Canopy Growth is graded F on this front, indicating that it is trading at a premium to its peers. Click here to see the values of some of the valuation metrics that have driven this grade.
Bottom LineThe facts discussed here and much other information on Zacks.com might help determine whether or not it's worthwhile paying attention to the market buzz about Canopy Growth. However, its Zacks Rank #3 does suggest that it may perform in line with the broader market in the near term.
Claybourne extends its market share momentum with expanded Frosted Flyers lineup
One of Canada’s fastest-growing cannabis brands adds new variety formats built for flavour, discovery and summer pre-roll season
SMITHS FALLS, Ontario--(BUSINESS WIRE)--Canopy Growth Corporation (“Canopy Growth” or the “Company”) (TSX: WEED) (Nasdaq: CGC) today announced that Claybourne’s Frosted Flyers Variety Pack has been awarded Best Infused Pre-Roll at the 2026 Grow Up Awards, presented during the annual Grow Up Conference & Expo in Toronto.
“Winning Best Infused Pre-Roll at Grow Up is a clear signal that consumers and the industry are responding to what Claybourne is building in Canada,” said Luc Mongeau, Chief Executive Officer, Canopy Growth.
Share Building on that recognition, the Company also announced the expansion of Claybourne’s Frosted Flyers infused pre-roll lineup in Canada, with three new 8-pack variety formats and the brand’s first bundle pack.
“Winning Best Infused Pre-Roll at Grow Up is a clear signal that consumers and the industry are responding to what Claybourne is building in Canada,” said Luc Mongeau, Chief Executive Officer, Canopy Growth. “Frosted Flyers was designed to bring more flavour and energy to the infused pre-roll category, and this recognition tells us we’re delivering on that. Today’s expansion extends our market share momentum, giving consumers more ways to discover the brand and more reasons to reach for Claybourne this summer.”
The expanded Frosted Flyers infused pre-roll lineup includes:
Frosted Flyers Podium Pack | 8x0.35g | Eight flavours, eight pre-rolls, one variety pack Frosted Flyers Fast Pack | 8x0.35g | Four sativa flavours, eight pre-rolls, two of each flavour Frosted Flyers Drag Pack | 8x0.35g | Four indica flavours, eight pre-rolls, two of each flavour Frosted Flyers Variety Bundle Pack | 2x5x0.5g | Five flavours, 10 pre-rolls, one cost-effective bundle pack With the addition of the Podium Pack, Fast Pack, Drag Pack, and Variety Bundle Pack, Claybourne is extending its position in multi-pack formats while meeting growing consumer demand for variety and convenience – expanding at a key seasonal moment.
“‘Built on Variety’ started as a product idea and has since evolved into a core part of our product identity,” said Jonathan Griffith, Co-Founder and VP of Marketing at Claybourne Co. “Consumers want options, and they want products that fit different occasions. These new 8x0.35g Podium, Fast and Drag packs build on that momentum with quicker sessions, more flavour rotation and curated experiences designed around how people actually consume.”
Availability
The new Frosted Flyers variety packs are now rolling out at select retail stores across Canada, with all formats available this summer.
About Canopy Growth
Canopy Growth is a world-leading cannabis company dedicated to unleashing the power of cannabis to improve lives. Its portfolio of owned and licensed brands including Tweed, 7ACRES, DOJA, Deep Space, Deelish, Claybourne, MTL Cannabis, Low Key by MTL and R’belle, as well as category defining Storz & Bickel, delivers innovative products to consumers across Canada and beyond.
Canopy Growth is one of Canada’s leading providers of medical cannabis services through Canada House Clinics and serves patients online via Abba Medix. The Company also holds an unconsolidated, non-controlling interest in Canopy USA, LLC, which provides exposure to the U.S. THC market.
Committed to quality, responsible use, and community, Canopy Growth is shaping a future where cannabis is embraced for its potential to enhance well-being.
Canopy Growth Corporation (“Canopy Growth” or the “Company”) (TSX: WEED) (Nasdaq: CGC) today announced that Claybourne’s Frosted Flyers Variety Pack has been awarded Best Infused Pre-Roll at the 2026 Grow Up Awards, presented during the annual Grow Up Conference & Expo in Toronto.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260608930080/en/
Frosted Flyers Variety Pack
Building on that recognition, the Company also announced the expansion of Claybourne’s Frosted Flyers infused pre-roll lineup in Canada, with three new 8-pack variety formats and the brand’s first bundle pack.
“Winning Best Infused Pre-Roll at Grow Up is a clear signal that consumers and the industry are responding to what Claybourne is building in Canada,” said Luc Mongeau, Chief Executive Officer, Canopy Growth. “Frosted Flyers was designed to bring more flavour and energy to the infused pre-roll category, and this recognition tells us we’re delivering on that. Today’s expansion extends our market share momentum, giving consumers more ways to discover the brand and more reasons to reach for Claybourne this summer.”
The expanded Frosted Flyers infused pre-roll lineup includes:
Frosted Flyers Podium Pack | 8x0.35g | Eight flavours, eight pre-rolls, one variety pack Frosted Flyers Fast Pack | 8x0.35g | Four sativa flavours, eight pre-rolls, two of each flavour Frosted Flyers Drag Pack | 8x0.35g | Four indica flavours, eight pre-rolls, two of each flavour Frosted Flyers Variety Bundle Pack | 2x5x0.5g | Five flavours, 10 pre-rolls, one cost-effective bundle pack With the addition of the Podium Pack, Fast Pack, Drag Pack, and Variety Bundle Pack, Claybourne is extending its position in multi-pack formats while meeting growing consumer demand for variety and convenience – expanding at a key seasonal moment.
“‘Built on Variety’ started as a product idea and has since evolved into a core part of our product identity,” said Jonathan Griffith, Co-Founder and VP of Marketing at Claybourne Co. “Consumers want options, and they want products that fit different occasions. These new 8x0.35g Podium, Fast and Drag packs build on that momentum with quicker sessions, more flavour rotation and curated experiences designed around how people actually consume.”
Availability
The new Frosted Flyers variety packs are now rolling out at select retail stores across Canada, with all formats available this summer.
About Canopy Growth
Canopy Growth is a world-leading cannabis company dedicated to unleashing the power of cannabis to improve lives. Its portfolio of owned and licensed brands including Tweed, 7ACRES, DOJA, Deep Space, Deelish, Claybourne, MTL Cannabis, Low Key by MTL and R’belle, as well as category defining Storz & Bickel, delivers innovative products to consumers across Canada and beyond.
Canopy Growth is one of Canada’s leading providers of medical cannabis services through Canada House Clinics and serves patients online via Abba Medix. The Company also holds an unconsolidated, non-controlling interest in Canopy USA, LLC, which provides exposure to the U.S. THC market.
Committed to quality, responsible use, and community, Canopy Growth is shaping a future where cannabis is embraced for its potential to enhance well-being.
For more information visit www.canopygrowth.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20260608930080/en/
